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ABSTRACT 
 
Introduction : 
  Infection with Human Immuno Deficiency Virus and its end stage 
Acquired Immuno Deficiency Syndrome are the major public health challenges of 
modern times. The HIV positive patients are extremely susceptible to a variety of 
opportunistic infections which  cause  morbidity and hospitalization. Though curative 
treatment for HIV is not available at present, we can minimize the HIV infection by 
early screening and health education. 
Aim & Objectives : 
To study the seroprevalence of HIV infection in Thanjavur by subjecting the 
serum samples to Rapid Card tests and confirm by ELISA. To determine the CD4 
counts of the reactive patients. To categorise the cases according to the presenting 
complaints and screen for Opportunistic Infections and do Molecular Characterisation  
for HIV-1. 
Materials & Methods : 
All cases were screened by COMB-AIDS kit at VCTC, TMCH, Thanjavur. 
Those  samples which test reactive to COMB-AIDS kit are subjected to HIV Triline, 
HIV Trispot & ELISA.CD4 counts of the reactive patients were detected. Zeihl – 
Neelsen staining of sputum, culture of oral swabs for Candida, Toxoplasma, HSV-2 
screening by ELISA, Cryptococcal latex agglutination test were done for reactive 
cases.Molecular Characterisation of HIV-1 was done for 10 samples. 
Results : 
Seroprevalence of HIV was 2.8%.Oral Candidiasis (39.02%) emerged as the 
most common Opportunistic Infection followed by Pulmonary Tuberculosis 
(28.03%), Herpes Simplex Virus -2 (14.45%) Toxoplasmosis (5.78%) and 
Cryptococcosis (3.41%). All 10 samples answered positive in PCR. 
Keywords: 
HIV, Seroprevalence, CD4 Count, Opportunistic Infections. 
 
 
 
 
 
INTRODUCTION 
Infection with Human Immuno Deficiency Virus and its end stage Acquired Immuno 
Deficiency Syndrome are the major public health challenges of modern times with 25 million 
people already dead and 30 to 40 million people living with HIV/AIDS(49). The illness was first 
described in 1981 and HIV-1 was isolated at the end of 1983. Since then AIDS has become a 
pandemic affecting different populations in different geographic regions. AIDS is one of the 
most important public health problems worldwide at the start of 21st century(31). 
The first case of AIDS in India was reported in 1986 and now India ranks second among 
world countries in HIV infection. India has an estimated 2.3 million HIV positive persons. 
Sexual route appears to be the major mode of transmission though injectable drug use is also 
emerging as an important mode of transmission in some parts of the country (35). Overall the 
average prevalence rate of HIV in India is 0.9% and it accounts for 10% of global HIV 
burden(56). 
HIV belongs to a family of human Retroviruses and the subfamily Lentivirus. The most 
common cause of HIV disease throughout the world is HIV-1. Both HIV 1 and HIV 2 are 
zoonotic infections. The Pan troglodytes troglodytes species of chimpanzees are the natural 
reservoir of HIV 1 and the most likely source of human infections(31).  
The HIV is spherical enveloped virus 80-100 nm in diameter. The core has two single 
stranded positive sense RNA, Reverse transcriptase, Protease and Integrase enzymes. The 
genome has three structural genes gag, pol and env and six non- structural proteins Vif, Vpu, Vpr 
tat, rev and nef(37). 
After entering a person’s body, HIV infects the cells and starts to replicate in the CD4 T 
cells and macrophages. It induces the body’s immune system to produce antibodies specific to 
HIV. The period between acquisition of infection and production of detectable HIV antibodies is 
called window period lasting for 2 to 12 weeks. During this period the person is highly infectious 
but may not test positive for common HIV antibody tests (56). 
At the time of infections 30 to 50% of persons have a recognizable acute illness. 
Symptoms of acute HIV infections include fatigue, rash, headache, nausea and night sweats. 
Because of the progressive destruction of CD4 lymphocytes and other immune cells, there is 
decline of immune response, patients with HIV are prone to develop a panorama of diseases 
during their life time (37). 
The HIV positive patients are extremely susceptible to a variety of opportunistic 
infections (35). These are called opportunistic infections because the advantage of the 
opportunity offered by a weakened immune system. Since the beginning of HIV epidemic, 
opportunistic infections have been recognized as common complication of HIV infection. 
Opportunistic infections cause substantial morbidity and hospitalization, necessitate toxic and 
expensive therapies and shorten the survival of people with HIV infection(14,34, 82).  
In India TB is the most common opportunistic infection among the HIV infected 
individuals. Other commonly reported opportunistic infections include Oral Candidiasis, Herpes 
zoster, Cryptococcal meningitis, Cerebral toxoplasmosis and Cytomegalovirus retinitis(50). 
The introduction of ART has dramatically reduced the incidence of opportunistic 
infections among the HIV infected individuals(61). However most of the people are living in 
areas with limited access to ART. The initiation of primary prophylaxis for opportunistic 
infections is based chiefly on CD4 count which has shown to be an excellent predictor of short 
term overall risk of developing AIDS among HIV infected patients(56). 
HIV infected people may remain asymptomatic for as long as ten or more years. People 
in this phase potentially play an important role in the transmission of HIV. They are infectious 
and cannot be identified by screening their serum for HIV antibodies (37). 
The lab diagnosis of HIV infection is based on the detection of HIV antibodies. A variety 
of HIV antibody assays are available like ELISA, Western blot and Rapid tests. Rapid tests are 
most appropriate for smaller health institutions. They are quicker and they do not require special 
instrumentation or training (56). 
HIV infection cannot be successfully diagnosed during the window period using antibody 
based assays. Assays which detect the virion are used in this phase. The tests employed are p24 
antigen and HIV proviral DNA assays. The proviral DNA assays is based on PCR which is 
highly sensitive and specific (56). 
Health education and case detection are presently the only ways to combat the 
catastrophe. Information, Education, Communication create awareness among general 
population(35).Hence I have undertaken this project to screen the patients for HIV infection and 
assess the clinical profile with respect to the presenting symptoms, CD4 count so that 
Opportunistic infections can be diagnosed early and treated thereby quality and expectancy of 
life can be improved.  
 
 
AIM & OBJECTIVES : 
1. To study the demographic profile of HIV in Thanjavur district, Tamil Nadu by screening 
the patients attending ICTC, TMCH, Thanjavur. 
2. To study the seroprevalence of HIV infection in Thanjavur by subjecting the serum 
samples to Rapid Card tests. 
3. To confirm the positive cases by ELISA. 
4. To determine the CD4 counts of the reactive cases. 
5. To categorise the cases according to the presenting complaints and screen for 
Opportunistic Infections. 
6. To study the molecular characterisation of HIV by RT-PCR. 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
HISTORICAL REVIEW : 
  HIV/AIDS is quite recently detected disease. This disease found its gateway in 
the mid 20th century. HIV is supposed to have spread from chimpanzees to humans in Africa. 
The virus is transmitted to humans following contact with blood of infected chimpanzees  during 
hunting (49). 
  For a long time HIV was present at low levels in equatorial Africa in 1950s, 
1960s, and early 1970s. A young Norwegian sailor travelled to African ports and he became ill. 
He transmitted the illness to his wife and his new born daughter. A Portugese man who visited 
Africa developed similar illness in 1974 (67). 
                     In 1981, five homosexual men with Pneumocystis jiroveci pneumonia were 
reported in Los Angeles(52). Kaposi’s sarcoma was reported in 26 homosexuals in New York & 
Los Angeles. The disease was named GRID (Gay Related Immuno Deficiency). Later the same 
illness was found among Injectable Drug Users and Blood transfusion recipients (31). 
  The etiological agent was named LAV(Lymphadenopathy Associated Virus) in 
France and HTLV-III in USA. International Committee for the Taxonomy of viruses 
recommended the current designation HIV(Human Immuno-deficiency Virus). In 1986, 
Zidovudine was developed. December 1, 1988 marked the first world AIDS day (6, 67). In 1991, 
dideoxycytidine was developed. In 1993, HIV first developed resistance to Zidovudine. In 1996, 
Nevirapine was approved. In 2000, trials for HIV vaccine started in Oxford. In 2003, Enfuvirtide 
was approved for HIV. 
GLOBAL SCENARIO : 
  Globally, 33.2 million people are currently living with HIV of which 30.8 million 
are adults and 2.5 million are children below 15 years. Among the 30.8 million, 15.4 million are 
women amounting to 50% of infections. 2.5 million people are newly infected every year with 
HIV of which 2.1 million are adults and 0.4 million are children(31). 
  The number of deaths due to AIDS continues to be alarmingly high and 2.1 
million lost their lives due to AIDS in 2008 of which 1.7 Million are adults and 0.4 million are 
children. (67) 
INDIAN SCENARIO : 
  The first case of HIV in India was diagnosed in Govt. General Hospital,  Chennai 
by Dr. Suniti Solomon in 1986(70). The patient was a Commercial Sex Worker from Mumbai. 
The seroprevalence of HIV is high in south and north-east. There is a great geographic variation 
of HIV infection in India. 
  About 2.3 million people are living with HIV of which 39.3% are women and 
60.7% are men, 86.5% are in the age group of 15-49 and 13.5% are less than 15 years(32, 78).  
  The epidemic is moving to general population from high risk group and to rural 
areas from urban. A wide variation is seen between states and even districts (32, 78). In South, 
the major mode of transmission is heterosexual whereas in North, it is IV drug abuse(32). 
   
 
TAMIL NADU SCENARIO (56): 
 About 2.1 lakhs people are living with HIV. The HIV prevalence among  
1. Ante Natal Cases- 0.25% 
2. Injectable Drug Users- 16.8% 
3. Men having Sex with Men- 6.6% 
4. Female Sex Workers – 3.6% 
 Namakkal is the worst affected district with the seroprevalence of 4.4% in 2003 and 2.8% in 
2004 because of its large trucking industry followed by Perambalur. 
  NACP-III (National AIDS Control Programme - III) classified the districts into 4 
categories A, B, C, D based on HIV prevalence (46). 
1. Category A – districts with > 1% ANC prevalence during the last 3 years. 
2.  Category B – districts with < 1% ANC prevalence during the last 3 years, with > 5% 
population in High Risk Group 
3. Category C – districts with < 1% ANC prevalence during the last 3 years, with <  5% 
population in High Risk Group with known hot spots ( Migrants, Truckers, Factory 
Workers & Tourists). 
4. Category D – districts with < 1% ANC prevalence during the last 3 years, with <  5% 
population in High Risk Group with no known hot spots. 
TN has 30 districts of which 22 districts come under Category A, 5 under Category B and 3 
under Category C. 
 
MORPHOLOGY OF HIV (24, 31, 49): 
The etiological agent of AIDS is Human Immunodeficiency Vir
family Retroviridae and subfamily L
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1. P 17(17kDa) – matrix protein 
2. P 24(24 kDa)- forming nucleo capsid shell 
3. P7, p6           - nucleoproteins tightly bound to viral RNA 
The core also has enzymes protease, Reverse  Transcriptase, Integrase, t RNA  and Vpr.  
HIV GENOME (39): 
The genome has various overlapping open reading frames coding for several viral proteins. It 
is 9.7 kb in length and has three genes gag, pol, env followed by two complete Long Terminal 
Repeats. The 5’ end begins with  
1. Gag gene – coding for four proteins p17, p24, p7, p6 followed by 
2. Pol gene – coding for Reverse Transcriptase (p66/51), Integrase(p32) and Protease(p10) 
followed by 
3. Env gene – coding for polyprotein gp160 which is then cleaved  into proteins gp120 and 
gp41 constituting the outer membrane of the virus(82). 
HIV also has six non- structural proteins like Tat, nef, rev, vif, vpu  
And Vpr. Between pol and env genes are located 
1. Vif – Viral Infectivity Protein – increases the infectivity of viral particles and degradation 
of viral DNA. 
2. Vpr – Viral protein r – enhances viral replication  
3. Tat – Transactivator of Transcription – major viral transactivator and produces immune 
suppression. 
4. Rev – regulator of expression of viral proteins and viral RNA 
5. Vpu – Viral protein u – enhances virion release and CD4 degradation. Located 
downstream from env gene is 
6. Nef – Negative Regulatory Factor – inhibits or enhances viral replication depending on 
the cell infected; anti apoptotic. 
The major difference between HIV-1 and HIV-2 is that HIV-2 lacks Vpu and has Vpx(42). 
 
 
 
 
 
MOLECULAR HETEROGENITY OF HIV-1 (31): 
 There are two major lentiviruses – HIV-1 and HIV-2. There are three major groups of 
HIV-1. 
1. Group M- Major – responsible for most of the infections 
2. Group O – Outlier – found in Cameroon, Gabon 
3. Group N – rare(33). 
HIV-1 is more closely related to viruses isolated from chimpanzees pan troglodytes troglodytes 
which are the natural reservoir of HIV-1. HIV-2 causing infections sporadically is more closely 
related to Cameroonian Gorillas (55). 
 The M group has nine subgroups or clades A, B, C, D, F, G, H, J, K and there are minor 
circulating recombinant forms (CRFs)(39). The prevalent CRF is CRF01_AE which is prevalent 
in South east Asia followed by CRF02_AG which is common in West and Central Africa. 
Subtype/ Clade B is seen in USA, Canada, Western Europe and Australia.  Subtype/ 
Clade C is the most common form worldwide and in India and is responsible for more than 50% 
of the infections. Usually an individual is affected by viruses of more than one subtype. Among 
HIV-2 there are five genotypes HIV2A to E. This molecular heterogeneity of HIV is due to the 
error prone nature of  Reverse Transcriptase. 
MODES OF TRANSMISSION OF HIV (31, 41, 67): 
  1. Unprotected sexual intercourse(heterosexual, homosexual) 
  2. Parenteral( use of inadequately sterilised syringes, needles) 
3. Perinatal ( From mother to child during pregnancy, delivery and breast feeding) 
SEXUAL TRANSMISSION : 
75 to 80% of HIV infection in adults are transmitted through unprotected sexual 
intercourse. (75) ( Heterosexual – 70% which is common in developing countries, Homosexual – 
5 to 10%  common in North America, Europe, Australia). 
There is strong association between anal intercourse and HIV as there is only a thin, 
fragile rectal mucous membrane separating semen from the cells which are the targets for HIV 
(75). Infection with microorganisms like Treponema pallidum, Haemophilus ducreyi, Neisseria 
gonorrhoea, Chlamydia, HSV, Trichomonas vaginalis cause genital ulcers which increase the 
risk of transmission of HIV. Treating Sexually Transmitted Diseases reduce the risk of  
transmission of HIV. 
PARENTERAL TRANSMISSION : 
Parenteral transmission during IV drug use does not require i.v. puncture. Even 
subcutaneous/ intramuscular injections also transmit infections. The sharing of infected needles 
transmit about 5-10% of infections. It is the dominant mode of transmission in developed 
countries and in developing countries blood transfusion is the cause (1). This can be decreased 
by screening the blood for viral nucleic acid, p24 antigen and antibodies.                    
Health Care Workers develop HIV by percutaneous injuries or by contact  of infected 
material with non intact skin or mucous membrane. The risk of transmission of HIV by 
percutaneous injuries is 0.3% and by mucocutaneous injuries is 0.09%.Factors associated with 
mucocutaneous transmission are exposure to large volume of blood, increased duration of 
contact with the infected material. 
 HIV can be transmitted by CSF, Synovial fluid, Pleural fluid, pericardial fluid, peritoneal 
fluid, amniotic fluid. Faeces, urine, tears, nasal creations, sweat saliva, sputum and vomitus are 
not  infectious if they are not bloody. 
 
PERINATAL TRANSMISSION: 
  Factors associated with perinatal transmission are advanced maternal stage, 
increased viral titres, decreased vitamin A levels, choriaamnionitis, maternal anaemia, placental 
malaria etc., In the absence of prophylactic ART, HIV can be transmitted from the mother to 
fetus in the first trimester. When the viral load is less than 1000 copies/ml, HIV is not 
transmitted to fetus but when the load increases to more than 1 lakh copies/ml, the rate of 
transmission increases to 40%.  
Zidovudine, when given to the mother from II trimester reduces the rate of transmission. 
Nevirapine given at the onset of labour to the mother, to the newborn within 72 hours of birth 
decreases the transmission rate. Caesarean delivery and giving artificial feeds also decrease the 
transmission.   
 
LIFE CYCLE OF HIV (31) : 
  The replication cycle of HIV consists of the following steps 
1. Attachment 
2. Penetration 
3. Uncoating 
4. DNA synthesis 
5. Nuclear transport 
6. Integration 
7. Particle Assembly and Budding. 
ATTACHMENT : 
The replication cycle begins with attachment of V1 region of gp120 to CD4 receptors and 
coreceptors CXCR4 and CCR5. This attachment produces a confirmational change of gp120 and 
it releases gp41 from high energy configuration. CXCR4 is the coreceptor for T cell tropic, 
synctitium forming viruses – X4 viruses, which are responsible for sexually transmitted 
infections. CCR5 is the coreceptor for macrophage tropic, non synctitium forming viruses – R5 
viruses, which are the dominant types in the later stage of disease resulting in rapid progression 
of the disease and death of the AIDS patient. 
PENETRATION : 
Gp41 fuses with host cell membrane and penetrates the plasma membrane of the target 
cell and brings the virion and target cell together. 
UNCOATING : 
Uncoating occurs by phosphorylation of viral matrix protein by MAP kinase. Nef causes 
changes in pH and promotes uncoating. At the end of uncoating viral RNA and enzymes are 
released from the cell membrane. 
DNA SYNTHESIS : 
As the viral particles traverses the cytoplasm and reaches the nucleus the viral Reverse 
Transcriptase catalyses the transformation of single stranded viral RNA into double stranded 
cDNA. The protein coat releases the DNA into the cytoplasm. In the viral RNA the arrangement 
is  
 LTR- 5’- gag,pol,env- 3’-LTR 
In the viral DNA the arrangement is as follows 
 U3-LTR- U5- gag,pol,env- 3’-LTR- 5’ 
 
 
NUCLEAR TRANSPORT : 
The double stranded DNA or the Pre- Integration Complex is 28nm in radius which is 
twice the radius of nuclear pore. So this transport requires Nuclear Localisation Signals located 
in the viral proteins especially vpr which disrupts the nuclear envelope and helps in the entry of 
Pre- Integration Complex into the nucleus. 
INTEGRATION : 
Viral double stranded DNA is inserted into host cell genome and provirus is formed. This 
reaction is catalysed by Integrase. This removes the terminal nucleotides from the DNA and 
inserts in the host genome. 
ASSEMBLY AND BUDDING : 
Viral proteins are assembled from outermost to innermost p17, p24, Protease, Reverse 
Transcriptase, Integrase. The nucleoprotein helps in encapsidation. Then gp160 cleaved in 
Endoplasmic Reticulum and Golgi Apparatus into gp120 and gp 41. 
Budding occurs in special regions of lipid layer called lipid rafts where the Nucleocapsid 
acquires the envelope. Protease catalyses the cleavage of gag and pol precursors and yields 
mature virion. 
IMMUNE RESPONSE (31) : 
Both Humoral and Cell mediated immunity play an important role in HIV infection. 
Humoral Immunity : 
1. Binding antibody 
2. Neutralising antibody – type and group specific 
3. ADCC antibody 
4. Enhancing antibody 
5. Complement 
Cell mediated Immunity : 
1. CD4 Helper T cells 
2. CD8 Cytotoxic T cells 
3. Natural Killer cells 
4. ADCC 
Humoral Immune Response : 
Antibodies appear within 6 to 12 weeks of infection. These are the binding antibodies 
detected by ELISA & Western Blot assay. The first antibodies detected are those formed against 
gag gene proteins p17 & p24 followed by antibodies to env gene proteins gp160, gp120, gp41 
and pol proteins p31, p51 and p66. Most of the neutralizing antibodies are formed against the 
hypervariable region of gp120 protein which is known as the V3 loop region. 
Antibodies which mediate Antibody Dependent Cell mediated Cytotoxicity and 
antibodies directed against gp41 also help infection of cells by HIV and this phenomenon is 
known as antibody enhancement. Certain antibodies kill the uninfected also along with infected 
cells and this is known as bystander killing. The infected cells are killed by Complement also. 
 
 
Cellular Immune Response : 
This is mediated by CD4 Helper T cells and CD8 Cytotoxic T cells. Though CD4 cells 
are the targets of HIV, they undergo proliferation and secrete IL-2 & IFN-γ. CD8 cells produce 
perforins and cause destruction of HIV infected cells bearing class I MHC molecules.CD8 cells 
inhibit the replication of HIV and this is mediated by chemokines MIP- 1α and MIP-1β. 
PATHOGENESIS OF HIV: 
   The main pathogenesis of HIV is the marked immune deficiency caused by destruction of 
CD4 Helper T cells (62). When the virus is transmitted by infected blood, contaminated needles 
and from mother to fetus, it enters the spleen from the circulation where it forms the primary 
focus. From there it goes to other lymphoid organs like GALT- Gut Associated Lymphoid Tissue 
producing initial viremia. 
When HIV is transmitted via sexual intercourse and infected breast milk then dendritic 
cells play a major role in the pathogenesis. These cells express a receptor DC-SIGN on their 
surface which binds to gp120 of HIV and trap the HIV particle within them. They retain the HIV 
particle for many days and mediate transinfection of CD4 cells. 
The virus starts replicating in the CD4 cells before specific immune response is mounted. 
This results in widespread dissemination of virus to brain and other tissues. The virus evades the 
immune system and starts replicating continuously for about ten years thus setting up chronic, 
persistent infection. 
CD4 count starts to decline but the patients are asymptomatic and this is known as 
clinical latency but there is no microbiological latency as there is always some level of virus is 
replicating. If the patients are not treated CD4 count starts progressively falling down and the 
patient becomes susceptible to opportunistic infections. 
LONG TERM SURVIVORS & LONG TERM NONPROGRESSORS : 
The patients living for more than 20 years after initial infection are long term survivors. 
They may have immuno deficiency, opportunistic infections even very low CD4 count. In spite 
of these they survive for more than 20 years. This may be due to ART and prophylaxis against 
opportunistic infections. 
The patients who have HIV infection for more than 10 years with normal CD4 counts  
and who are stable  without ART are long time non progressors. This may be due to efficient 
humoral and cell mediated immune responses against the viruses. 
NATURAL COURSE OF HIV (41) : 
The course of HIV is defined three phases which occur over a period of 10 years which 
include : 
1. Primary HIV infection 
2. Chronic asymptomatic phase 
3. Overt AIDS 
Primary HIV infection : 
This stage is characterised by initial rise in plasma viremia to more than 1million 
copies/ml, decrease in CD4 cells in blood and tissues and increase in blood CD8 cells. Virus 
specific immune responses are mounted resulting in decrease of plasma viral load. This causes 
resolution of clinical syndrome.HIV antibodies are negative and so the diagnosis is based on p24 
assay and the detection of plasma viral RNA. 
Chronic asymptomatic phase :  
The first phase is followed by the phase of clinical latency. In this phase the viral load 
and CD4 counts are stable. The virus replicates at low levels in the gut and they are trapped in 
the Follicular Dendritic Cells in the lymphoid tissue. The ability of the immune system to 
maintain effective and specific immune responses is impaired. As a result of this the levels of 
viremia rapidly rise and CD4 count fall progressing towards the advanced stage with 
constitutional symptoms and opportunistic infections. 
Overt AIDS : 
This is the end stage of HIV infection leading to death in 2-3 years in the absence of 
ART. CD4 falls below 50cells/ml. 
CLINICAL MANIFESTATIONS OF AIDS : 
Early Stage : 
This stage is usually asymptomatic or the patient may experience mild flu like symptoms. 
This acute clinical syndrome is characterised by fever, fatigue, arthralgia, headache, rash, 
lymphadenopathy, pharyngitis, myalgia, night sweats, gastrointestinal disturbances, oral/genital 
ulcers and the CD4 counts are above 500cells/ml. In 80-90% of patients the illness is very mild 
that they do not seek medical attention. 
 
Intermediate Stage : 
This stage is also asymptomatic or without serious manifestations. CD4 counts are 
between 200-500 cells/ml. Skin and mucosal infections are common. Herpes simplex, Herpes 
zoster, Oral/vaginal Candidiasis, Oral Hairy Leucoplakia, respiratory tract infections caused by 
Streptococcus pneumoniae, Pelvic Inflammatory Disease occurs in this stage. Patients experience 
fever, diarrhoea and weight loss. These manifestations are referred to as “ AIDS Related 
Complex.” 
Late Stage : 
This stage is defined by CD4 count below 200 cells/ml and presence of AIDS defining 
illness. 
WHO Classification System for HIV Infection (67) : 
Clinical Stage I      
1. Asymptomatic Infction 
2. Persistent Generalised Lymphadenopathy 
3. Acute Retroviral Infection 
Performance Stage I 
Asymptomatic, normal activity level 
Clinical Stage II 
1. Unintentional Weight loss < 10% of body weight 
2. Minor mucocutaneous manifestations (dermatitis, angular cheilitis, fungal nail infections) 
3. Herpes zoster within last 5 years 
4. Recurrent upper respiratory tract infections 
Performance Stage II 
Symptomatic but fully ambulatory 
Clinical Stage III 
1. Unintentional Weight loss > 10% of body weight 
2. Chronic diarrhoea > 1 month 
3. Fever > 1 month 
4. Oral Candidiasis 
5. Oral Hairy Leucoplakia 
6. Pulmonary TB 
7. Severe bacterial infectons 
8. Vulvo vaginal Candidiasis 
Performance Stage III 
In bed more than usual 
Clinical Stage IV 
1. HIV wasting syndrome 
2. Pneumocystis jiroveci pneumonia 
3. Toxoplasmosis of brain 
4. Cryptosporidiasis with diarrhoea > 1 month 
5. Isosporiasis with diarrhoea > 1 month 
6. Cryptococcosis, extrapulmonary 
7. Cytomegalovirus infection of an organ other than liver, spleen or lymph node 
8. Herpes Simplex infection, mucocutaneous 
9. Progressive Multifocal Leucoencephalopathy 
10. Any disseminated endemic mycosis 
11. Candidiasis of esophagus, trachea, bronchus, lung 
12. Atypical Mycobacterial infection 
13. Non typhoid Salmonella septicaemia 
14. Extrapulmonary TB 
15. Lymphoma 
16. Kaposi’s Sarcoma 
17. HIV encephalopathy 
Performance Stage IV 
In bed > 50% of daytime 
OPPORTUNISTIC INFECTIONS (31,41)  : 
These infections are named so as they take the advantage or opportunity of weakened 
immune system. These infections are the major causes of mortality and morbidity in HIV. 
TUBERCULOSIS (17, 41) : 
HIV infection is an important risk factor for the development of Tuberculosis. It increases 
the risk of activation of latent TB and also the risk of primary disease following exogenous 
infection. In India there are a large number of new TB cases and 5% of these are coinfected with 
HIV.HIV patients with TB are less infectious as they have only non-cavitating lesions. 
CD4 cells play a major role in the immunity against TB including the formation of 
epithelial granulomas which restrict the growth of the organism and these cells are very much 
depleted in HIV infection which in turn facilitates the fluorishing growth of M.tuberculosis(59). 
Host immune response to M.tuberculosis promotes HIV replication. So the both microorganisms 
mutually help each other. 
Sites of TB disease like granulomas create favourable environment for HIV replication. 
Host responses against M.tuberculosis like secretion of proinflammatory cytokines like TNF, 
activation of mononuclear cells in turn favours tremendous replication of HIV. So both HIV and 
TB infections go hand in hand. 
Clinical features of TB in HIV patients with normal CD4 counts are similar to HIV 
negative individuals with TB(85). With progressive fall of CD4 counts atypical presentation of 
pulmonary TB, sputum smear negative TB, extrapulmonary TB, miliary TB predominate. 
Cervical, Inguinal, mediastinal lymphadenopathy, pleural, pericardial effusions, abscesses in 
liver, spleen are also common. 
Candidiasis : 
Oral Candidiasis is seen in most of the HIV patients, esophageal Candidiasis in advanced 
stage and vulvovaginal Candidiasis in one fourth of the women. Most of the infections are 
caused by C.albicans. The most common presentation is creamy white patches on an 
erythematous base. Patients with oesophageal Candidiasis experience difficulty in swallowing 
whereas in vulvovaginal Candidiasis patients complain of vaginal discharge, itching and burning 
pain. 
Oral Candidiasis in HIV patients is a sign of progressive immune Deficiency(41,71). 
ART should be started along with anti fungal therapy like fluconazole or itraconazole. 
Esophageal Candidiasis requires systemic therapy. If ART is not started, relapses are common. 
Herpes Simplex infection : 
Herpes reactivation occurs in advanced disease when CD4 falls below 100. It is 
characterised by painful ulcers at mucocutaneous junctions followed by ulcerations. Recurrent 
genital, perirectal ulcers are common due to reactivation of HSV-2.Most infections are treated 
with oral aciclovir for 5-14 days and severe mucocutaneous infections are treated with 
intravenous aciclovir. Herpes zoster can occur at any stage of HIV infection. The lesions are 
bullous or haemorrhagic and severely painful along a single dermatome. 
Toxoplasmosis : 
This is common in advanced disease when CD4 count falls below 100 cells/ml. This is 
caused by Toxoplasma gondii, an obligate intracellular parasite. It occurs as a result of activation 
of latent T.gondi. CNS is the common site of Toxoplasmosis. Toxoplasmic encephalitis occurs as 
single or multiple intracranial abscesses with focal neurologic signs and constitutional 
symptoms. Fever, headache, confusion, lethargy, seizures are common. Diagnosis is by MRI and 
ELISA for anti-toxoplasmal antibodies. Treatment is a combination of Pyrimethamine & 
Sulfadiazine for 3-6 weeks. 
 
Cryptosporidiasis : 
It is more prevalent in poorly developed countries and common in HIV when CD4 count 
goes below 50 cells/ml. It is caused by a protozoa Cryptosporidium parvum, tranmitted by fecal-
oral route. Cryptosporidiasis is characterised by diarrhoea which may range in severity from mild 
diarrhoea to cholera like watery diarrhoea accompanied by abdominal cramps, nausea, vomiting 
and anorexia. Diagnosis is based on the identification of the parasite in the stool by Modified 
acid fast staining (10, 20). Treatment is symptomatic and ART is must for restoration of immune 
status. 
Cryptococcosis : 
This is caused by Cryptococcus neoformans when CD4 falls below 50 cells/ml. 
Cryptococcosis presents as subacute meningitis or meningoencephalitis with fever, malaise, 
headache, neck stiffness, altered mental status, photophobia, lethargy and memory loss. 
Diagnosis is by detection of cryptococcal antigen in CSF. 1:8 titre is significant. If not treated, 
the condition is fatal. It is treated by Amphotericin B(0.7mg/kg) intravenously  for 2 weeks 
followed by Fluconazole 400mg orally for 8 weeks. ART is essential. Immune Reconstitution 
Syndrome is common when ART is instituted after Cryptococcal infection(36). 
Pneumocystis jiroveci Pneumonia : 
This occurs typically when CD4 count falls below 200cells/ml and more common in 
USA than in other parts of the world. It presents with progressive dyspnoea, dry cough, mild 
fever and weight loss. Diagnosis is by Chest Radiography where an interstitial infiltrate from 
perihilar to peripheral region is seen. Fibre optic bronchoscopy with bronchoalveolar lavage or 
transbronchial lung biopsy is done to demonstrate the morphology of the organism. 
Trimethoprim 15mg/kg/day and Sulfmethoxazole 75mg/kg/day is given in three divided doses 
for 21 days. Corticosteroids may be added in case of moderate to severe disease. However it is 
ideal to start TMP-SMX regimen prophylactically when CD4 falls to 200 cell/ml. 
Cytomegalovirus Infections : 
Retinitis is the most common manifestation of CMV infection which typically occurs 
when CD4 falls below 50 cells/ml. It causes progressive necrotising retinitis first in one eye then 
affects the other eye also. The patients complain of floaters, blurring of vision and finally 
blindness. The virus also affects   gastro intestinal tract causing esophageal, gastric, duodenal 
ulcers and entero-colitis. In the CNS, it causes CMV polyradiculopathy and CMV 
ventriculoencephalitis. In the lungs, pneumonitis is common. Treatment is i.v. ganciclovir 
followed by oral valganciclovir. 
Mycobacterium Avium Complex : 
MAC infection is common when CD4 count goes below 100 cells/ml. It is acquired 
through ingestion or inhalation. In HIV infection, involvement of gut is  common leading to 
nausea, vomiting, watery diarrhoea. Dissemination is more common in MAC infections 
characterised by  fever, night sweats and weight loss. Blood culture is diagnostic. 
Clarithromycin/azithromycin + Ethambutol + Rifabutin is the treatment usually given for life. 
Bacterial Pneumonia : 
It is caused by S.pneumoniae, H.influenzae, M.catarrhalis, K.pneumoniae, S.aureus. In 
addition Chlamydiae, Nocardiae, Legionellae, Rhodococcus equi are also associated. The patient 
experiences fever, cough and pleuritic chest pain. Blood cultures are more diagnostic than 
sputum cultures. Treatment is Vancomycin 1g i.v. or Ciprofloxacin 750 mg orally. 
Skin Infections: 
These include impetigo, folliculitis, cutaneous abscesses, subcutaneous and soft tissue 
abscesses. Cauasative organisms are Staphylococcal and Streptococcal sp. Treatment is surgical 
drainage and appropriate antibiotics. 
Bacillary angiomatosis is characterised by erythematous nodules caused by Bartonella 
henselae, B.quintana. Treatment is Erythromycin 500mg 4 times a day or Doxycycline 100mg bd 
for 1-2 months. 
Enterocolitis : 
Bacteria responsible for causing enterocolitis in HIV are non-typhoid 
Salmonella(S.typhimurium), Shigella, Campylobacter jejuni, Clostridium difficile. The 
manifestations include severe diarrhoea, abdominal cramps, nausea, fever. Treatment is 
Ciprofloxacin 500mg bd for 2-4 weeks. For C.difficile Vancomycin or Metronidazole is the drug 
of choice. 
Progressive Multifocal Leucoencephalopathy : 
This is a demyelinating illness caused by JC virus. The virus causes lysis of 
oligodendrocytes and breakdown of myelin producing white lesions in the brain. Diagnosis is by 
brain biopsy or PCR of CSF. There is no antiviral treatment but ART should be given. 
 
Neoplasms : 
Neoplasms common in HIV infection are Kaposi’s sarcoma and Non Hodgkin’s 
lymphoma followed by Multiple myeloma, melanoma, cervical, skin, oral and lung cancers. 
Kaposi’s Sarcoma : 
 It is characterised by many reddish purple nodules in skin, mucous membrane and 
viscera. The lesions vary in size from a few millimeters to several centimeters and are common 
in sun exposed areas and in areas of trauma. Skin, lymphnode, lungs and gastro intestinal tract 
are commonly affected followed by heart and CNS. Diagnosis is by biopsy of the histology 
showing extravasation of RBCs and proliferation of spindle and endothelial cells. Treatment is 
indicated only when the lesion overlies a joint or when it causes discomfort, cosmetic problems, 
difficulty in swallowing & breathing. It is treated by localised radiotherapy and intralesional 
Vinblastine. In other cases ART is enough. 
Lymphomas : 
These occur when CD4 count goes below 200 cells/ml. Three types of lymphoma are 
common in HIV – immunoblastomas, Burkitt’s lymphoma, Primary CNS Lymphoma. 
Immunoblastomas account for 60% of the cases presenting as ascites, pleural or pericardial 
effusion without lymphadenopathy. Burkitt’s lymphoma  contributes 20% of cases and Primary 
CNS Lymphoma another 20%. The clinical features of lymphoma in HIV ranges from fever, 
night sweats, weight loss to focal neurological deficits. 
 
 
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)  : 
After starting ART, instead of clinical well being there is deterioration of the patient’s 
health condition and worsening of Opportunistic infections. This usually occurs 2 weeks – 2 
years of starting ART and is most common in patients in whom ART is started when CD4 count 
is under 50 cells/ml. 
IRIS may be due to an untreated mycobacterial infection in the patient. The pathogenesis 
of IRIS may be due to a mechanism simulating Type IV hypersensitivity reaction. It may cause 
localised lymphadenopathy, fever, infiltrates in the lung, increased intracranial pressure, Grave’s 
disease and uveitis. IRIS may end fatal. In severe cases, glucocorticosteroids and other 
immunosuppressive drugs are given (31).  
LABORATORY DIAGNOSIS OF HIV (2, 31, 51) : 
By early 1985, antibody based tests were developed in USA, by 1996 p24 antigen capture 
assay was developed and by 2002, nucleic acid testing was developed. The diagnosis of HIV 
depends on detection of  HIV antibodies and direct demonstration of HIV or one of its 
components. Antibodies to HIV start to appear from 2-12 weeks of infection (31).  
Specimen Collection & Transport : 
For HIV-1 & 2 antibody testing and p24 antigen testing, about 5ml of  clotted blood is 
sufficient. The samples must be properly labeled. If any delay in transport is anticipated, the 
Samples can be stored at room temperature for 3 days at 4°C. For viral RNA assays, 10ml of 
whole blood in EDTA tubes or 5ml of plasma is sufficient and can be stored at 2-25°C and 
transported to the laboratory within 48 hours as the viral DNA starts to denature. 
The HIV test should be done for  
1. Patients with TB, especially young 
2. Patients with Sexually Transmitted Diseases (STD) 
3. Antenatal care patients 
4. Patients with Hepatitis B,C 
5. History of high risk behaviour / transfusion. 
DIAGNOSTIC TESTS : 
Antibody based tests : 
Screening tests 
1. ELISA 
2. Rapid tests 
Supplemental tests 
1. Immunofluorescent assay 
2. Western blot  
3. Line Immuno assay 
4. Radio Immuno Precipitation Assay 
Other tests : 
1. P24 antigen tests 
2. Polymerase Chain Reaction (PCR) 
3. Plasma /serum viral load 
 
Alternative tests : 
1. Saliva HIV tests 
2. Urine HIV tests 
ELISA : 
This is the widely used sensitive test for HIV infection because of its high sensitivity. The 
antigen is coated on microtitre wells. The test serum is added. If antibodies are present, it binds 
to the antigen. After washing, anti human immunoglobulin linked to a suitable enzyme is added 
followed by a colour forming substrate. If the test serum contains anti HIV antibodies, a colour is 
formed which can be detected visually.  There are four generations of  ELISA. 
1. First generation – whole viral lysate 
2. Second generation – Recombinant antigen 
3. Third generation – synthetic peptide 
4. Fourth generation – antibody + p24 antigen (HIV duo) 
Using first and second generation ELISA, antibodies can be detected in 6-12 weeks. With third 
generation ELISA, antibodies can be detected in 3 weeks. With fourth generation ELISA since it 
detects p24antigen also HIV can be diagnosed in 2 weeks. But ELISA has the disadvantage 
producing false positive and false negative results. 
RAPID TESTS : 
These tests yield results within 30 minutes. When performed correctly, they are accurate. 
The results can be read by naked eye. These tests are useful in emergency room, autopsy room 
and smaller blood banks. 
Advantages : 
Rapid tests are useful in 
1. Labour room 
2. Mass screening. 
3. Detecting HIV-2 also. 
Disadvantages : 
1. Subjective interpretation 
2. A colour blind cannot interpret. 
WESTERN BLOT : 
This assay is based on the fact that various HIV antigens of different molecular weight 
induces the production of specific antibodies. The antibodies to each component produces a 
band. So the HIV proteins are separated according to their molecular weight and electrophoretic 
mobility by polyacrylamide gel electrophoresis and blotted on strips of nitrocellulose paper. The 
strips are reacted with test sera and then  with anti human immunoglobulin conjugated with 
enzyme. A suitable substrate is then added which produces a colour band where specific 
antibody has reacted with the separated viral antigen. The position of the band indicates the 
antigen with which the antibody has reacted. 
Interpretation : 
Positive Western Blot Criteria : 
1. WHO – 2 env with/without gag/pol 
2. CDC – Any two p24, gp41, gp120, gp160 
Negative – no bands 
Indeterminate – bands present but does not satisfy the criteria. 
P24 ANTIGEN TEST : 
P24 antigen tests are also EIA based and use antibodies to capture the disrupted antigen. 
This antigen appears as early as two weeks and lasts for 3-5 month and so this test shortens the 
window period. 
This test is useful : 
1. During the window period 
2. To detect HIV infection in newborn 
3. During late disease when the patient is symptomatic. 
Disadvantages : 
1. Low sensitivity 
2. Repeat tests needed for confirmation 
PCR : 
 In this the target HIV RNA or proviral DNA is amplified enzymatically invitro by 
chemical methods. It is extremely sensitive as a single copy of DNA can be amplified. HIV 
nucleic acid is detectable as early as 12 days. Three different techniques are available RT-PCR, 
Nucleic Acid Sequence Based Amplification(NASBA) and branched DNA Assay. 
            HIV RNA measurement by PCR requires initial conversion of viral RNA into cDNA by 
addition of exogenous Reverse Transcriptase followed by PCR amplification and quantification 
of the product. The commercially available RNA detection kits have a sensitivity of 40-80 
copies/ml plasma. 
Uses : 
1. In hypogammaglobulinemia 
2. In advanced disease 
3. Drug resistance in HIV 
4. Genotyping & Sequence analysis. 
HIV DIAGNOSIS IN NEWBORNS : 
Serologic diagnosis of HIV in newborn is difficult because anti HIV antibody coming 
from the mother persist for  18 months. If DNA PCR is positive within first 2 days, it is 
diagnostic of infection in utero. In infection during delivery, PCR is negative at 48 hours and 
positive within one month. In case of p24 antigen false positives are common in neonates. So it 
is inferior to PCR. For diagnosis in newborns, PCR should be done at 48 hours, 1 week, 3 
months and six months and it should be confirmed by serology at 18 months. 
NEWER TESTS : 
ORASURE- SALIVA HIV TEST : 
Non-invasively collected specimens like oral fluid, saliva and oral mucosal transudate are 
used. These systems detect antibodies comparable to or exceeding serum samples. 
  
 
URINE TESTS : 
IgG antibodies are found in urine. The collection of urine is simple, noninvasive and so 
more useful in developing countries where trained technicians are not available for collecting 
blood. 
LAB MONITORING OF PATIENTS WITH HIV INFECTION : 
CD4 COUNT : 
CD4 count measures the degree of immunosuppression. CD4 progressively declines as 
the immune function decreases. It is used in staging the disease, monitoring disease progression, 
serves as a guide to start ART, determining treatment failure. CD4 cell count is the best predictor 
of disease progression and it is cheaper than viral load. So it is useful in developing and poor 
nations (66).  
The WHO 2010 recommendations states that all HIV positive adults  with CD4 count less 
than 350 cells/ml should be started on ART with or without symptoms. WHO defines 
immunological failure as fall of CD4 count to baseline or below or 50% decrease of CD4 count 
from on treatment peak value or persistent CD4 count below 100 cells/ml. 
The U.S. CDC uses CD4 count and divides AIDS into three categories A, B, C. Category 
A CD4 count >500 cells/ml, Category B CD4 count 200-499 cells/ml, Category C CD4 count 
<200 cells/ml. According to CDC, AIDS is HIV infection with CD4 count < 200 cells/ml or 
CD4% < 14%. But WHO staging does not include CD4 count to accommodate poor nations (45). 
 
 
HIV VIRAL LOAD : 
It is a direct measure of in vivo replication of virus and therefore it is a powerful 
prognostic tool (26). Measurement of viral load is based on getting the target RNA, Reverse 
Transcription of RNA into cDNA, PCR amplification of target DNA and detection of dual 
fluorescent labeled oligonucleotide probes which quantifies HIV-1 target RNA. The test can 
detect and quantitate HIV-1 RNA as few as 40-50 copies/ml of plasma. Therapy is considered in 
patients with more than 1,00,000 copies/ml. During therapy, viral load is determined every 3-4 
months. Reduction of viral load less than 50 copies/ml in 6 months indicates effective treatment. 
Uses : 
1. Guide for initiating ART 
2. Optimising the duration of treatment. 
3. Switching to second line of treatment 
4. Diagnosing HIV infections in children < 18 months. 
HIV DRUG RESISTANCE TESTING (31, 67) : 
It measures the sensitivity of individual’s HIV to different ARV agents which can be 
measured by phenotypic and genotypic methods. In genotypic assays, sequence analysis of 
patient’s HIV is compared with sequence of virus with known ARV resistance profiles. In 
phenotypic methods the in vivo growth of the virus is compared with reference strains in the 
presence and absence of ARV agents. 
Uses : 
1. Selecting an initial regimen for treatment of new patients 
2. Selecting new drugs in drug failure 
TREATMENT : 
The treatment of HIV includes counseling to the patient  and ART. 
Counseling : 
1. The first and foremost is the emotional support to the patient to overcome the 
psychological blow. 
2. Up – to date information about the disease, its severity should be given to the patient. 
3. The need to start ART, its benefits, side effects should be informed. 
Anti Retro Viral Therapy (31, 81) : 
The main aim of ART is to suppress viral load so that the quality of life of the patient can 
be improved and the duration of life can be prolonged (18). If the HAART regimens are strictly 
followed, many opportunistic infections can be prevented.  
Classification of drugs : 
1. Drugs inhibiting the viral reverse transcriptase enzymes 
a. Nucleoside Reverse transcriptase inhibitors- Zidovudine, didanosine, Zalcitabine, 
Stavudine, Lamivudine, abacavir. 
b. Non –Nucleoside Reverse transcriptase inhibitors – Nevirapine, Delaviridine, 
Efavirenz. 
c. Nucleotide Reverse transcriptase inhibitors – Tenofovir. 
2. Drugs inhibiting Protease enzyme – Ritonavir, Indinavir, Saquinavir, Amprenavir, 
Lopinavir, Nelfinavir,Atazanavir, Darunavir. 
3. Drugs inhibiting Integrase enzyme – Raltegravir 
4. Drugs inhibiting Viral entry – Maroviroc 
5. Drugs inhibiting Fusion of viral envelope with host cell- Enfuvirtide. 
Nucleoside Reverse transcriptase inhibitors : 
These drugs enter the host cell and are phosphorylated into their respective triphosphate 
forms, inhibit the Reverse Transcriptase by competing with our host nucleosides  and cause the 
chain termination of  viral DNA. 
DRUG DOSAGE TOXICITY 
Zidovudine 300 mg bd Anaemia, Neutropenia, myopathy, lactic 
acidosis, hepatomegaly 
Didanosine 200mg bd 1 hour 
before food. 
Pancreatits, Peripheral neuropathy, lactic 
acidosis, hepatomegaly. 
Zalcitabine 0.75 mg tds Pancreatits, Peripheral neuropathy, lactic 
acidosis, hepatomegaly, oral ulcers. 
Stavudine 40 mg bd Pancreatits, Peripheral neuropathy, lactic 
acidosis, hepatomegaly, lipodystrophy. 
Lamivudine 150 mg bd Hepatotoxicity 
Emtricitabine 200 mg qd Hepatotoxicity 
Abacavir 300 mg bd Fatal hypersensitivity, fever, rash 
 
Non- Nucleside Reverse Transcriptase Inhibitors :  
  These drugs need not undergo intracellular phosphorylation and directly act on 
the RT enzyme at a different site and inhibit it. These are non-competetive inhibitors. They are 
not active against HIV-2. These drugs when used alone develop resistance quickly so always 
used in combination with other drugs. 
 DRUG 
 
DOSAGE TOXICITY 
 
Delavirdine 
 
400 mg tds Skin rashes, Hepatotoxicity 
Nevirapine 200 mg/day for 14 days then 200 mg bd Skin rashes, Hepatotoxicity 
Efavirenz 600 mg od before food Skin rashes, Hepatotoxicity, depression, abnormal dreams. 
 
Nucleotide Inhibitors : 
Tenofovir is a newer drug and is the only nucleotide analogue. It is used in a dose of 300 
mg qd. It is most effective and lest toxic. It is used when Zidovudine or Nevirapine cannot be 
used due to contraindications. However it can cause nephrotoxicity on prolonged use. 
Protease Inhibitors : 
Protease cleaves the large viral polyproteins into structural proteins and enzymes. These 
drugs inhibit the cleaving function of protease. These are more effective than NRTIs. As these 
drugs act on late stage of HIV replication cycle, they act on both newly and chronically infected 
cells. 
 
DRUG DOSAGE 
 
TOXICITY 
 
Saquinavir 1000mg+100mg ritonavir bd 
Diarrhoea, Nausea, Abdominal pain, Head ache, fat 
redistribution, Lipid abnormality 
Ritonavir 600mg bd Nausea, Abdominal pain, Head ache, fat 
redistribution, Lipid abnormality 
Indinavir 800mg+100mg ritonavir bd 
Nephrolithiasis Indirect hyperbilirubinemia fat 
redistribution, Lipid abnormality. 
Nelfinavir 1250mg bd Nausea,Diarrhoea, hyperglycemia fat redistribution, Lipid abnormality 
Amprenavir 
600mg+100mg Ritonavir 
bd 
 
Nausea, Abdominal pain, Head ache, fat 
redistribution,Lipidabnormality hyperglycemia 
Lopinavir 100mg bd Nausea, Abdominal pain, Head ache, fat 
redistribution,Lipidabnormality,hyperglycemia 
Atazanavir 400mg qd Hyperbilirubinemia, nausea, PR prolongation, hyperglycemia, fat redistribution 
Tipranavir 500mg+200mg Ritonavir bd 
Diarrhoea,fatigue, skin rash, headache, 
Hepatotoxicity,Intracranial haemorrhage. 
Darunavir 600mg+100mg Ritonavir bd Diarrhoea, nausea, headache 
 
Integrase Inhibitors : 
Integrase enzyme cuts the host DNA and integrates the viral DNA with it. Raltegravir 
inhibits this enzyme. There is no cross resistance with other ARV drugs and it is used against 
both HIV-1 & HIV-2. It is given in a dose of 400 mg bd. When used in combination with other 
drugs, it quickly produces an increment in CD4 count and decrement in  HIV RNA levels. Side 
effects are nausea, rash. 
Fusion  Inhibitors : 
Enfuvirtide binds with gp41 inhibits the fusion of viral envelope with the plasma 
membrane of host cells thus the viral entry into the host cells is prevented. It is not active against 
HIV-2. No cross resistance with other drugs is observed. It is used in patients who failed to 
recover with previous regimens. Dosage is 90mg bd subcutaneously. Disadvantages are it is 
costly, painful causing nodules at injection sites. 
Entry Inhibitors : 
Maroviroc is a new drug that blocks the CCR5 receptor of host cells and the attachment 
and viral entry into the host cells are inhibited. So useful only against R5 viruses and not active 
against X4 viruses which use CXCR4 receptor. Receptor tropism assays are performed before 
using it. It is used in patients with multiple drug resistant CCR5 tropic HIV infections. Dosage is 
150-600 mg bd orally. Side effects are hepatotoxicity, fever, rash, abdominal pain, 
immunosuppression as it involves the human chemokine receptor. 
Therapeutic Regimen : 
1. ART when started, it should be with 3 drugs belonging to 2 different classes. 
2. For patients who are started on ART, Protease Inhibitors are not used. PIs(Low dose 
Ritonavir boosted PIs) are used for patients who failed earlier regimens. 
3. In cases of side effects, the causative drug or the entire regimen may be changed. In case 
of treatment failure the entire regimen is changed. 
4. Treatment is life-long. 
5. In pregnancy, the drugs like Zidovudine, Lamivudine, Nevirapine, Nelfinavir and 
Saquinavir are relatively safe. 
6. The universally preferred first line regimen is 2NRTIs + 1NNRTI. The preferred  
 
 
 
 
 
NACO RECOMMENDED FIRST LINE REGIMEN : 
1. PreferredRegimen Lamivudine + Zidovudine + Nevirapine 
2. Alternative Regimen 
Lamivudine + Zidovudine + Nevirapine 
Lamivudine + Stavudine + Efavirenz 
Lamivudine + Stavudine + Nevirapine 
3. Other options 
Lamivudine + Tenofovir + Nevirapine 
Lamivudine + Tenofovir + Efavirenz 
Lamivudine + Zidovudine + Tenofovir 
 
If the patient is anaemic, Stavudine is used instead of Zidovudine. 
When Zidovudine & Stavudine are contraindicated, Tenofovir is used. 
Efavirenz is used in those with liver dysfuntion and those using Rifampicin. 
Nevirapine is used in pregnant women. 
When Efavirenz & Nevirapine  are contraindicated, 3 NRTIs are used (2). 
Indications for Changing Regimen : 
1. When plasma RNA drops less than a log or increases significantly after 4 weeks of 
initiation of therapy. 
2. Decreasing CD4 counts 
3. Clinical deterioration 
4. Drug Toxicities 
 
Second line Regimen : 
Drug susceptibility testing is done for choosing the optimal regimen. It is measured by 
phenotypic or genotyping methods. Phenotypic assays measure the activity of viral enzymes in 
the presence or absence of different concentrations of drugs. Genotyping assays done by DNA 
chip hybridisation & line probe assays. A Ritonavir boosted PI is included. Maroviroc, 
Enfuvirtide, Raltegravir may be considered in cases of repeated failures. 
SECOND LINE REGIMENS : 
NRTI PI 
1. Tenofovir + Abacavir 
2. Didanosine + Abacavir 
3. Tenofovir + Zidovudine 
4. Tenofovir + Lamivudine 
Lopinavir/r 
Atazanavir/r 
Saquinavir/r 
Indinavir/r 
 
POST – EXPOSURE PROPHYLAXIS : 
Health care personnel who are accidently exposed to the risk of  HIV are considered for 
PEP. The goal of PEP is to suppress viral replication so that wide spread dissemination and 
infection is prevented. 
 
 
Low risk 
Exposure through mucous membrane, 
superficial scratch, thin needle when the 
source is asymptomatic with high CD4 & low 
RNA 
Zidovudine 300mg + 
Lamivudine 150mg bd for  
4 weeks 
High risk 
Exposure through large splash, large area of 
mucous membrane, abraded skin, large bore 
needle when the source is symptomatic with 
high RNA & low CD4 
Zidovudine 300mg bd + 
Lamivudine 150mg bd + 
Indinavir 800 mg tds for  
4 weeks 
 
Perinatal Prophylaxis : 
              NACO first line regimen for HIV positive pregnant women is Zidovudine + Lamivudine 
+ Nevirapine. For those who are not on ART, Zidovudine 300mg bd  is started during the second 
trimester and continued through delivery, postnatal period and the neonate is treated for 6 weeks  
DRUG RESISTANCE : 
Resistance is common when monotherapy instead of combination therapy is given and 
when the replication rate of virus is high. It is due to mutations of the aminoacids of viral 
enzymes. The resistance to NRTIs may be due to a mutation in the Reverse Transcriptase 
enzyme that  identifies the drug and prevents the attachment of the drug to the primer. The other 
mechanism is mutation in the enzyme that increases the removal of NRTIs. A mutation in the 
hydrophobic pocket of  the Reverse Transcriptase enzyme prevents the binding of  NNRTIs .A 
mutation in the protease enzyme produces structural changes in the enzyme so the affinity 
between drug and enzyme is reduced. Drug resistance is monitored by CD4 counts, HIV RNA 
levels and PCR. 
 
VACCINES (31, 67) : 
There is not a safe, effective vaccine for HIV till now because of the following reasons : 
1. The immune response does not clear HIV infection in turn causes superinfection. This 
also holds good for the vaccine immunity. 
2. High mutation rate of virus due to error prone nature of  Reverse Transcriptase. 
3. Different strains of HIV are prevalent worldwide. There is no international cooperation to 
produce a candidate vaccine that is suitable for the strains prevalent in developed and 
developing countries. 
4. The vaccines are greatly needed in developing countries where the people are poor and 
have the least ability to pay. 
     
 
 
 
 
 
 
 
 
MATERIALS & METHODS 
STUDY PLACE : 
This study was conducted among cases attending Voluntary Counseling Testing Centre, 
Thanjavur Medical College Hospital. 
STUDY PERIOD : 
The study period was 1 year from September 2012 to September 2013. 
STUDY POPULATION : 
The study population includes 346 HIV positive patients detected by antibody test. 
STUDY DESIGN : 
 Observational study. 
ETHICAL CONSIDERATIONS : 
Written consent to participate in the study was obtained from the patients or their 
guardians after full explanation of the study. This study was reviewed by Institutional Ethical 
Committee, Thanjavur Medical College, Thanjavur. All data were handled confidentially and 
anonymously. 
INCLUSION CRITERIA :  
Cases attending VCTC , TMCH, Thanjavur like 
1. Cases referred from the Surgical specialities for HIV testing as a part of routine 
screening. 
2. Cases referred from Medical wards with history suggestive of HIV. 
3. Cases referred from ENT and dental OPD with signs of oral thrush. 
4. Cases referred from skin OPD with herpes like lesions. 
5. Cases referred from STD clinics with genito urinary lesions. 
6. All Cases with sputum smear positivity referred from TB cell . 
7. Spouses of HIV reactive cases. 
 
EXCLUSION CRITERIA : 
1. Antenatal mothers. 
2. Neonates born to HIV positive mothers. 
3. Patients on Anti Retro Viral therapy. 
4. Cases of chronic diarrhea not responding to routine antibiotics. 
Clinical data were collected from all patients. 
SAMPLE COLLECTION : 
After giving pretest counseling and obtaining written consent from the patient, 5ml of 
blood was collected from the patients by intravenous route with universal precautions and 
transferred to sterile screw capped vials. The caps were fixed with adhesive tape to prevent 
leakage during transport. The blood samples were transported to the lab immediately in an ice 
box with proper labeling (name of the patient, identification number, date of collection ) 
 
 
SAMPLE PROCESSING : 
The samples were taken to the laboratory immediately and they were allowed to clot by 
placing in a rack at room temperature (20 - 25°C) for at least 30 minutes. After that serum was 
separated by centrifugation. The clarified serum was then transferred to a sterile vial and was 
stored at +4°C (short term storage) and at -70°C (long term storage). 
METHODS : 
• All cases were screened by COMB-AIDS kit at VCTC, TMCH, Thanjavur. 
• Those samples which test reactive to COMB-AIDS kit are subjected to PAREEKSHAK 
HIV 1/2 TRILINE CARD test at VCTC, TMCH, Thanjavur. 
• Those samples which  test reactive to the second test are subjected to AIDSCAN HIV 1/2 
TRISPOT TEST KIT procedure at VCTC, TMCH, Thanjavur. 
• The samples are further confirmed by HIV ELISA. 
• CD4 counts of the reactive patients were detected by BD-FACS counter at ART centre, 
TMCH, Thanjavur.  
• The sputum of the patients with symptoms of cough, fever and weight loss were screened 
for Pulmonary Tuberculosis by Zeihl – Neelsen staining.  
• Oral swabs were taken from those with oral thrush and streaked on SDA. 
• All the samples were screened for Toxoplasmosis by Toxoplasma IgG ELISA. 
• All the samples were screened for HSV-2 by HSV-2 IgG ELISA. 
• All the samples were screened for Cryptococcosis by  Latex Agglutination Test. 
• AMPLICOR HIV-1 DNA PCR, version 1.5was run for 10 samples to detect HIV-1 DNA. 
 
COMB – AIDS – RS ADVANTAGE – ST: 
This test kit is an in-vitro, visually read dot immunoassay for qualitative detection of 
antibodies to HIV in blood, serum or plasma. 
Principle : 
It employs the principle of dot immunoassay where the immobilized antigen – antibody 
complex is visualized by a colored end point produced by Colloidal gold – Protein A signal 
reagent. Each tooth of the comb has two circular spots, one near the tip of the comb blended with 
synthetic peptides or recombinant antigens of HIV(Test spot) and the other spot little above the 
first spot blended with the control reagent (Control spot). A positive test result is indicated by a 
pink spot/dot in the test spot near the tip of the comb. 
REAGENTS/ACCESSORIES IN THE KIT : 
Reagents : 
1. Washing buffer 
2. Colloidal gold signal reagent 
3. Sample diluent 
4. Positive control 
5. Negative control 
6. Antigen & control coated combs 
 
 
 
ASSAY PROCEDURE : 
1. All kit components and samples are brought to room temperature. 
2. Add 2 drops of sample diluent to each micro test wells. 
3. Add 2 drops of sample to each of the above well. 
4. Place the required number of combs into respective wells. 
5. Incubate for 10 minutes at room temperature. 
6. Wash the combs in buffer solution 
7. Add 4 drops of colloidal gold reagent in another micro test wells. 
8. Place the combs in micro test wells containing colloidal gold signal reagent. 
9. Incubate for 10 minutes at room temperature. 
10. Wash the combs in buffer solution. 
INTERPRETATION : 
Positive Result : 
 This is indicated by the presence of pink colored spot or dot both in the test and control 
spot. 
     Negative result : 
 This is indicated by the presence of pink colored spot or dot in the  control spot alone. 
Indeterminate result : 
  This is indicated by the presence of faint pink colored spot or dot both in the test and 
control spot. In this case, the test should be repeated. If the result is still indeterminate, fresh 
sample is taken after 4-8 weeks and tested again. 
Invalid result : 
This is indicated by the absence of pink coloured spot or dot  in the  control area   
irrespective of presence or absence of pink coloured spot or dot in test area. 
PAREEKSHAK  HIV 1/2 TRILINE CARD TEST : 
It is an immuno chromatography based assay for detection of antibodies to HIV-1 and 
HIV-2. 
Principle  : 
This test follows lateral flow immuno- chromatography. The test device has a sample 
window with a reagent releasing pad which is held in contact by a porous membrane 
material. The membrane has four zones. The first zone is mobile and it is at the sample 
window and it consists of gold particles sensitised with HIV antigens. The second and third 
zones(Test line) has recombinant HIV antigens(recombinant HIV gp-41antigen and C 
terminal of gp120 for HIV-1& recombinant HIV-2 gp36 for HIV-2) immobilised on the 
membrane. The fourth zone has(control line) has control antibody immobilised on the 
membrane.  
If the sample has antibodies they form a complex with HIV antigen conjugated gold, 
move on trapped by test line and a red line is formed. The unbound colloidal gold particles 
continue to move due to capillary action, come in contact with the control line, trapped 
giving rise to a red line demonstrating the validity of the test. 
 
 
CONTENTS OF THE KIT : 
1. Testing device 
2. Diluent 
3. 10 µl dropper 
4. Silica gel 
5. HIV – 1&2 positive control 
6. HIV – 1&2 negative control 
ASSAY PROCEDURE : 
1. Bring the kit and samples to room temperature. 
2. Remove the test device from the pouch just before the test. 
3. Place the device on a flat surface. 
4. Add a 1drop of serum or plasma into the sample window and allow it to soak in. 
5. Add 2 drops of diluent into the sample window. 
6. Read the results in 20 minutes. 
INTERPRETATION OF RESULTS : 
Negative result : 
 The presence of only one band at ‘C’ indicates negative result. 
Positive result : 
 The presence of a band at ‘C’ and bands at ‘1’ and /or at ‘2’ indicates positive result for 
HIV-1 or HIV-2. 
Invalid result : 
 If the control band is not visible and only the test band is visible, then the test is invalid. 
 
HIV ELISA MICROLISA : 
This is developed to detect anti-HIV envelope antibodies to HIV-1 and HIV-2 with equal 
reactivity. The core proteins show cross reactivity and envelope proteins are found in all persons. 
So in this test antibodies to envelope proteins like gp41, C terminus of gp120 and gp36 are 
detected. 
Principle : 
HIV envelope proteins are coated on the surface of microtitre wells. If the patient’s 
sample has anti-HIV antibodies, it will bind to the antigen. After washing to remove the unbound 
material, anti human immunoglobulin conjugated with HRP is added which binds only to the 
antigen – antibody complex. Then the substrate containing chromogen and hydrogen peroxide is 
added and incubated. A blue colour develops in proportion to the amount of HIV-1 or HIV-2 
antibodies. The reaction is read at a wavelength of  450 nm. If the sample does not contain 
antibody then the conjugate will not bind and no colour develops. 
COMPONENTS IN THE KIT : 
1. Microwells coated with HIV-1 & HIV-2 recombinant proteins. (12x8 wells) 
2. Sample diluent 20ml. 
3. Anti – human immunoglobulin coated with Horse Radish Peroxidase – 0.25ml 
4. Conjugate diluent 15 ml 
5.  Wash buffer 50ml 
6. TMB substrate 10ml 
7. TMB diluent 10 ml 
8. Positive control 2ml – inactivated diluted patient’s serum positive for HIV antibodies. 
9. Negative control 2 ml – normal serum negative for HIV, HbsAg, HCV. 
10.    Stop solution – 15 ml 
11.  Plate sealers. 
TEST PROCEDURE : 
1. Add 100µl sample diluent to A-1 as blank. 
2. Add 100µl Negative control to B-1 & C-1 wells. 
3. Add 100µl Positive control to D-1, E-1& F-1 wells. 
4. Add 100µl sample diluent in each well starting from G-1followed by addition of 10µl 
sample. 
5. Apply cover seal. 
6. Incubate at 37°C for 30 minutes. 
7. Wash the wells 5 times. 
8. Add 100µl of  working conjugate in each well from A-1. 
9. Apply cover seal. 
10.  Incubate at 37°C for 30 minutes. 
11. Add 100µl working substrate in each well from A-1. 
12.  Incubate at room temperature for 30 minutes in dark. 
13.  Add 100µl stop solution. 
14. Read absorbance at 450 nm within 30 minutes in ELISA reader. 
INTERPRETATION OF RESULTS: 
1. Cut-off value is calculated is by adding mean negative control and mean positive control 
and the sum is divided by 6. 
2. Test specimens with absorbance less than the cut-off value are non reactive and negative 
for anti-HIV. 
3. Test specimens with absorbance equal to or greater than the cut-off value are  reactive  
for anti-HIV. 
4. This is a screening test and should be confirmed by Western blot as false positive results 
are caused by Leprosy, TB, Herpes simplex virus, lipemic serum. 
CD4 DETERMINATION BY BD-FACS COUNT SYSTEM 
The BD-FACS Count System for use with the BD FACS Count CD4/CD3 reagent kit is 
an automated instrument designed for enumerating the absolute cell counts of CD4 and CD3 T 
lymphocytes in unlysed whole blood. 
Principle : 
When whole blood is added to the reagents, fluorochrome – labeled antibodies in the 
reagents bind specifically to lymphocyte surface antigens. When the sample is run on the 
instrument, the cells come in contact with the laser light which cause the fluorochrome – labeled 
cells to fluoresce(45). Analysis is automatic and the software calculates the absolute counts. 
Results are print immediately.  
 
 
MATERIALS REQUIRED : 
Materials provided : 
1. Coring station – opens the reagent and control tubes to prepare them for use. 
2. Electronic Pipette – delivers 50µl fluid. 
3. Software protocol floppy discs  
4. Workstation – holds blood samples and operating supplies. 
5. System fluid – saline solution flowing through the fluidics 
6. Thermal printer paper 
7. Waste reservoir 
8. Cleaning tubes and dispensing bottles. 
PROCEDURE : 
1. For each patient sample, label a reagent tube with patient accession number. 
2. Vortex each tube upside down for 5 seconds. 
3. Open each reagent tube with coring station. 
4. Invert each BD vacutainer tube 5 to 10 times to adequately mix the blood. 
5. Pipette 50µl whole blood into each reagent tube. 
6. Cap each tube and vortex upright for 5 seconds. 
7. Incubate the tubes for 60 to 120 minutes at room temperature 
8. Pipette 50µl fixative solution into each one. 
9. Recap each tube and vortex upright for 5 seconds. 
10. Place the tube in the sample holder of the instrument. 
11. Press run. 
12. When the analysis is complete, the results are displayed. 
ZEIHL – NEELSEN STAINING : 
1. Primary staining with is done with strong Carbol fuschin for 5-7 minutes with 
intermittent heating. 
2. Decolourising agent 20% Sulphuric acid is added and kept for 2 minutes. 
3. Counter staining is by adding methylene blue and keeping it for 3 minutes. 
Grading of the smear : 
 
No. of bacilli 
 
Grade 
No bacilli in 300 fields Negative 
1 -2 bacilli/ 300 fields Doubtful, Repeat the smear. 
1-9 bacilli  / 100 fields 1+ 
1-9 bacilli / 10 fields 2+ 
1-9 bacilli/field 3+ 
10 or more /field 4+ 
 
 ORAL CANDIDIASIS : 
1. Those patients with oral thrush were asked to rinse their mouth. 
2. Two swabs were taken from the lesion. 
3. One swab was used for Gram staining which shows budding gram positive cells with 
pseudohyphae. 
4. The other was used to streak it on the Saburaoud’s Dextrose Agar and Incubated at 37°C 
for 24 hours. Cream colored, smooth, pasty colonies appear. Gram staining from the 
colonies shows budding gram positive cells with pseudohyphae.   
TOXOPLASMA IgG ELISA : 
IgM & IgG antibodies to Toxoplasma can be detected with 2-3 weeks of exposure. IgG 
antibodies remains positive but the antibody level drops. 
Principle : 
Diluted serum is added to wells coated with purified Toxoplasma antigen. Toxoplasma 
IgG antibody if present, binds to the antigen. All unbound materials are washed away and 
enzyme conjugate is added which binds to antigen antibody complex, then substrate is added. 
The  intensity of colour generated is proportional to the amount of  IgG specific antibody in the 
sample. 
MATERIALS IN THE KIT : 
1. Microwells coated with Toxoplasma – 12X8 wells. 
2. Sample diluent – 22ml 
3. Calibrator – 1ml 
4. Positive control – 1ml 
5. Negative control – 1ml 
6. Enzyme conjugate – 12ml 
7. TMB substrate – 12ml 
8. Stop solution – 12ml 
9. Wash concentrate 20X – 25ml 
ASSAY PROCEDURE : 
1. Bring all specimens and reagents to room temperature. 
2. Place the desired number of coated strips in the holder. 
3. Prepare 1:21 dilution of the test samples by adding 10µl sample to 200µl diluent. Mix 
well. 
4. Dispense 100µl diluted sera, calibrator and controls to appropriate wells. 
5. Incubate for 20 minutes at room temperature. 
6. Wash wells 3 times. 
7. Dispense 100µl of  enzyme conjugate in all wells. 
8. Incubate for 20 minutes at room temperature. 
9. W ash wells 3 times. 
10. Dispense 100µl of  TMB substrate in all wells. 
11. Incubate for 10 minutes at room temperature. 
12.  Add 100µl stop solution. 
13.  Read the absorbance at 450 nm. 
INTERPRETATION OF RESULTS : 
Calculation : 
1. Cut-off value = Calibrator OD X Calibrator factor  
2. Antibody index is calculated by dividing the OD value of the sample by cut-off value. 
3. Antibody index < 0.9 – No detectable IgG antibody to Toxoplasma by ELISA. 
4. Antibody index 0.9-1.1 : Borderline positive. Follow up needed if clinically indicated. 
5. Antibody index > 1.1 – Detectable IgG antibody to Toxoplasma by ELISA. 
HSV-2 IgG ELISA : 
This is intended for the detection of  IgG antibodies to HSV-2 in human serum or plasma. 
The presence of IgG is indicative of previous exposure. A significant increase in IgG is 
indicative of reactivation, current or recent infection. 
Principle : 
Diluted serum is added to wells coated with purified antigen.  IgG specific antibody if 
present, binds to the antigen. All unbound materials are washed away and enzyme conjugate is 
added which binds to antigen antibody complex. Substrate is added and the plate is incubated to 
allow hydrolysis of substrate by enzyme. The  intensity of colour generated is proportional to the 
amount of  IgG specific antibody in the sample. 
MATERIALS IN THE KIT : 
1. Microwells coated with HSV-2 antigen – 12X8 wells. 
2. Sample diluent – 22ml 
3. Calibrator – 1ml 
4. Positive control – 1ml 
5. Negative control – 1ml 
6. Enzyme conjugate – 12ml 
7. TMB substrate – 12ml 
8. Stop solution – 12ml 
9. Wash concentrate 20X – 25ml 
ASSAY PROCEDURE : 
1. Bring all specimens and reagents to room temperature. 
2. Place the desired number of coated strips in the holder. 
3. Prepare 1:21 dilution of the test samples by adding 10µl sample to 200µl       diluent. Mix 
well. 
4. Dispense 100µl diluted sera, calibrator and controls to appropriate wells. 
5. Incubate for 20 minutes at room temperature. 
6. Wash wells 3 times. 
7. Dispense 100µl of  enzyme conjugate in all wells. 
8. Incubate for 20 minutes at room temperature. 
9. W ash wells 3 times. 
10. Dispense 100µl of  TMB substrate in all wells. 
11. Incubate for 10 minutes at room temperature. 
 12. Add 100µl stop solution. 
13. Read the absorbance at 450 nm. 
INTERPRETATION OF RESULTS : 
Calculation : 
1. Cut-off value = Calibrator OD X Calibrator factor  
2. Antibody index is calculated by dividing the OD value of the sample by cut-off value. 
3. Antibody index < 0.9 – No detectable IgG antibody to HSV-2  by ELISA. 
4. Antibody index 0.9-1.1 : Borderline positive. Follow up needed if clinically indicated. 
5. Antibody index > 1.1 – Detectable IgG antibody to HSV-2  by ELISA. 
CRYPTOCOCCAL LATEX AGGLUTINATION TEST : 
  Cryptococcal meningitis is a common opportunistic infection in AIDS. This test 
detects the Cryptococcal antigen in patient’s serum or plasma. 
 
Principle : 
Latex particles coated with anticryptococcal globulin reacts with Cryptococcal Polysaccharide 
antigen causing visible agglutination. 
MATERIALS IN THE KIT : 
1. Latex particles coated with rabbit anti – cryptococcal globulin. 
2. Negative control – normal human serum negative for HIV, HCV, HBsAg. 
3. Positive control – Purified Cryptococcal neoformans polysaccharide. 
4. Cards 
5. Applicator stick. 
 
 
PROCEDURE : 
1. Remove the cards from the pack. 
2. Label the cards as Negative control, Positive control and sample. 
3. Add a drop of  negative control, positive control and sample to designated rings. 
4. Add a drop of  latex to all the rings. 
5. Rock the slide back and forth with hand or rotator at a speed of 125 rpm. 
6. Read the agglutination titre. 
INTERPRETATION : 
a. Negative – homogenous with no clumping 
b. +1 – Fine granulation against a milky background. 
c. +2 – Small clumps against cloudy background. 
d. +3 – Large & small clumps against clear background. 
e. +4 - Large clumps against clear background. 
AMPLICOR HIV-1 DNA PCR : 
Sample Preparation : 
HIV-1 DNA is isolated by washing the whole blood sample to extract the leucocytes 
which are then lysed in a detergent solution containing Proteinase K. 
PCR Amplification : 
This uses the primers SK145 and SKCC1B to define a sequence of 155 nucleotides 
within the highly conserved region of the HIV-1 gag gene. PCR amplification is performed with 
thermostable recombinant enzyme Thermus thermophilus DNA polymerase in presence of 
manganese and appropriate buffer conditions. 
 
Hybridization Reaction : 
Following PCR amplification, the HIV-1 amplicon is denatured to form single stranded 
DNA by adding denaturing solution. Aliquots of denatured amplicon  are added to separate wells 
of microtitre plates coated with HIV-1 specific oligonucleotide probe. The biotin labeled HIV-1 
amplicon are hybridised to target specific oligonucleotide probes bound to wells of the MWP. 
Detection Reaction : 
Following the hybridisation reaction, the MWP is washed to remove unbound material 
and Avidin HRP Conjugate is added to each well of MWP. The Avidin HRP Conjugate binds to 
the biotin labeled HIV-1 amplicon  hybridised to target specific oligonucleotide probes bound to 
wells of the MWP. The MWP is washed and substrate solution containing Hydrogen Peroxide 
and 3,3’,5,5’- tetramethyl benzidine is added to the wells. In presence of  Hydrogen Peroxide, the 
bound HRP catalyses the oxidation of TMB to form coloured complex. The reaction is stopped 
by addition of a weak acid and the  absorbance at 450nm is measured. 
REAGENTS : 
Specimen Preparation Reagents: 
1. Wash solution 
2. HIV- 1 Extraction Reagent (Tris- KCl buffer, 0.1% detergent,0.01% Proteinase K) 
 
Amplification Reagents: 
1. HIV-1 master mix (Glycerol, <0.01% rTth polymerase, <0.07%  dATP, dCTP, dGTP, 
dTTP, dUTP, <0.001% SK145 and SKCC1B biotinylated primers) 
2. Manganese solution 
3. HIV-1 positive control – non infectious DNA containing HIV-1 sequences 
4. HIV-1 negative control – non infectious mammalian DNA. 
5. HIV-1 internal control – non infectious plasmid DNA. 
6. Avidin Horse Radish Peroxidase Conjugate 
7. Substrate – TMB 
8. Stop solution 
Detection Reagents : 
1. HIV-1 Micro Well Plate coated with HIV-1 specific DNA probe SK102. 
2. HIV-1Internal Control Micro Well Plate coated with IC specific DNA probe CP35 
3. Denaturation solution – 1.6% sodium hydroxide, EDTA, Thymol blue 
4. HIV-1 Hybridisation buffer 
5. Avidin – HRP 
6. Substrate A solution – 0.01% Hydrogen Peroxide 
7. Substrate B solution – 0.1% TMB 
8. Stop solution – 4.9% sulphuric acid 
PROCEDURE : 
Reagent Preparation : 
1. Place the reaction tubes in the MicroAmp tray and arrange in coloumns of 8 tubes each. 
2. Prepare working Master mix by adding 100µl HIV-1 manganese solution to a vial of 
HIV-1 MMX. Recap the tube and invert it 10-15 times. 
3. Add 50µl working Master mix into each reaction tube. 
 
S ample and Control Preparation: 
1. Add 1ml of BLD WS to 2ml screw cap tubes 
2. Invert the tube of whole blood 10-15 times for mixing thoroughly. 
3. Pipette 500µl whole blood into a tube containing BLD WS. 
4. Incubate 5 minutes at room temperature. 
5. Microcentrifuge the tubes for 3 minutes at maximum speed. 
6. Aspirate the supernatant and add 1ml BLD WS to resuspend the pellet. 
7. Repeat steps 5&6. 
8. The dry pellet is extracted. 
9. Working extraction reagent is prepared by adding 6ml HIV-EXT and 80µl HIV-IC and 
vortex the mixture for 10 seconds. 
10. Add 200µl Working extraction reagent to each pellet, HIV-1 PC, HIV-1 NC and vortex. 
11.  Incubate the tubes at 60°C for 30 minutes in a dry sand block. 
12. Incubate the tubes at 100°C for 30 minutes in a dry sand block. 
13.  Vortex the samples. 
14. Microcentrifuge the samples for 3 seconds. 
15.  Remove MicroAmp trays from plastic bags. 
16.  Add 50µl of samples and controls to appropriate reaction tubes. 
17.  Move prepared samples and controls in the MicroAmp tray to the 
Amplification/Detection area. 
Amplification : 
1. Place the tray into thermal cycler block for 90 minutes. 
2. Remove the tray from thermal cycler. 
3. Add 100µl denaturation solution to the reaction tubes. 
4. Incubate for 10 minutes at room temperature. 
Detection : 
1. Warm all reagents to room temperature. 
2. Prepare  working wash solution by adding 10X WB to 9 ml distilled water. 
3. Allow HIV-1 MWP and HIV-1 CT MWP to warm to room temperature. 
4. Add 100µl HIV-1 HYB to each well on the MWP.  
5. Pipette 25µl of denatured amplicon to appropriate wells of  the MWP. Gently tap it 10-15 
times till the blue colour changes to yellow. 
6. Incubate for 1 hour at 37°C. 
7. Wash the MWP 5 times. 
8. Add 100µl AV-HRP to each well. 
9. Incubate at 37°C for 15 minutes. 
10. Prepare working substrate by mixing 2ml of Substrate A and 0.5ml of Substrate B. 
11.  Wash the MWP 5 times. 
12. Add 100µl working substrate to each well of MWP. 
13.  Incubate at room temperature for 10 minutes. 
14. Add 100µl stop solution to each well of MWP. 
15.  Measure the absorbance at 450nm. 
 
 
INTERPRETATION : 
HIV result 
A450nm IC result A450nm Interpretation 
< 0.2 >0.2 HIV -1 DNA not detected 
<0.2 <0.2 Inhibitory sample. Should be repeated. 
>0.8 ANY HIV-1 DNA detected. Sample is positive for HIV-1 DNA. 
>0.2, <0.8 ANY Equivocal. Duplicate testing performed. 
 
 
 
 
 
 
 
 
               RESULTS 
This study was carried out among 11953 cases attending VCTC of a tertiary care hospital, 
Thanjavur Medical College Hospital and  over a period of one year. 
• 11953 cases attending VCTC, TMCH, Thanjavur were analysed over a period of one year 
from September 2012 to September 2013. 
• Of the 11953 cases, 346 cases were found to be reactive for HIV by Comb AIDS, HIV 
Triline and HIV Trispot. 
• Among the 346 reactive cases, 346 cases were reactive for HIV-1, 1 case was reactive for 
both HIV-1 & HIV-2 and none were  reactive for HIV-2 alone. 
• All the 346 cases reactive to HIV by Comb AIDS, HIV Triline and HIV Trispot were 
also reactive by HIV Microlisa. 
• The prevalence of HIV in this study over a period of one year was 2.8%. 
• In this study, out of the 346 reactive cases 207(59.83%) were males and 139 (40.17%) 
were females.(Table 2) 
• The male to female ratio was 1.48:1. 
• The majority of the reactive cases, 146 (42.20%) out of 346 were in the age group of 31 
to 40 years  followed by 84 cases (24.28%)  in the age group of 41 to 50 years.(Table 3) 
• Among the reactive 8 (2.31%) were children. 
• On the basis of habitat, people coming from rural areas (77.17%) outnumbered the urban 
population (22.83%) (Table 4) 
 
• The education wise distribution showed that 113(32.66%) were illiterates  123(35.55%) 
were educated upto primary level, 68(19.65%) were educated upto secondary level and 
35(10.12%) were graduates.(Table 5). 
• Among the males, majority were farmers(35.27%) followed by laborers(33.33%) and 
drivers(17.40%). 
• Among the females, majority were house wives(88.49%) .(Table 6) 
• The distribution of the subjects showed that 312(90.17%) out of 346 were married and 
21(6.07%) were unmarried. (Table 7) 
• Heterosexual route (97.11%) was the major mode of transmission, 8 cases(2.31%) by 
perinatal transmission and 2 cases(0.58%) gave history of blood transfusion. (Table 8)  
• According to the first CD4 count at the time of registration at the ART centre, the 
minimum CD4 count was 16 cells/ml and the maximum CD4 count was 1092 cells/ml 
with the mean CD4 count of 388.6 cells/ml.  
• 90 of 346 cases (26.01%) had CD4 count > 500 cells/ml. 
• 256 of 346 had CD4 count < 500 cells/ml, consisting of 80 (23.12%) with CD4 count 
between 350-500, 80(23.13%) with CD4 count between 201-350, 58 (16.76%) with CD4 
count between 101 -200 and 23 (6.65%) with CD4 count between 51 – 100 and 
15(4.34%) with CD4count < 50 cells/ml.(Table 8) 
• The mean CD4 count of  males is 389.67 and the mean CD4 count of females is 409 and 
the mean CD4 count of females is higher than that of males. 
• The most common clinical presentation was fever(57%), weight loss (45%), oral 
thrush(35%), cough (15%) and primary generalised lymphadenopathy (10%). 
 
• Among  the HIV positive patients, 135 cases(39.02%) had oral thrush with mean CD4 
count 409.97 and candida was grown when the swabs were streaked in SDA (Table 10, 
11). 
• Among the reactive cases, 97(28.03%) of them showed sputum smear positivity for 
Pulmonary Tuberculosis with the mean CD4 count 173.37 (Table 12, 13). 
• Among the 346 sera screened for Herpes Simplex Virus -2 by IgG ELISA, 50 
cases(14.45%) were reactive  for HSV-2 with a mean CD4 count of 194.18 cells/ml 
(Table 14, 15). 
• Among the 346 sera screened for Toxoplasmosis by IgG ELISA, 20 cases(5.78%) were 
reactive with a mean CD4 count of 182.35 cells/ml (Table 16, 17). 
• Among the 346 sera screened for Cryptococcosis by Latex Agglutination test, 12 
cases(3.41%) were reactive with a mean CD4 count of 96.58 cells/ml (Table 18, 19). 
• So in my study the most common Opportunistic Infection among the HIV positive 
patients is Oral Candidiasis  followed by Pulmonary Tuberculosis, Herpes Simplex 
Virus-2, Toxoplasmosis and Cryptococcosis. 
• Ten whole blood samples with CD4 count less than 200 were subjected to HIV-1PCR 
and all the samples answered positive. 
Table – 1. SEROPREVALENCE OF HIV 
Total No. of cases 
tested HIV Positive Cases Prevalence (%) 
11953 346 2.8% 
 
Prevalence Rate = 346/11953 X 100 = 2.8% 
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Table -2 
SEX WISE DISTRIBUTION OF HIV CASES 
 
 
  S.NO 
 
SEX 
 
NUMBER 
 
PERCENTAGE 
1. Male 207 59.83% 
2. Female 139 40.17% 
 
Majority of the affected cases are males. 
TABLE – 3 
AGE WISE DISTRIBUTION OF HIV CASES 
S.No Age group Total Male Female 
1. 0-10 years 8 5 3 
2. 11-20 years 7 5 2 
3. 21-30 years 53 29 24 
4. 31-40 years 146 73 73 
5. 41-50 years 84 61 23 
6. 51-60 years 41 29 12 
7. 61-70 years 6 4 2 
8. > 70 years 1 1 0 
 
Majority of the affected males and females are in the age group of 31-40 years. 
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TABLE – 4 
HABITAT WISE DISTRIBUTION OF HIV CASES 
 
 
S.NO 
 
RURAL/URBAN 
 
TOTAL 
 
 
MALE 
 
FEMALE 
 
1. 
 
Rural 
 
267 
 
159 
 
108 
 
2. 
 
Urban 
 
79 
 
48 
 
31 
 
Majority of the affected cases belong to rural areas. 
TABLE – 5 
EDUCATION WISE DISTRIBUTION OF HIV CASES 
 
S.NO 
 
EDUCATION 
 
TOTAL 
 
MALE 
 
FEMALE 
 
 
1. 
 
Child 
 
7 
 
4 
 
3 
 
2. 
 
Illiterate 
 
113 
 
60 
 
53 
 
3. 
 
Primary 
 
123 
 
79 
 
44 
 
4. 
 
Secondary 
 
68 
 
37 
 
31 
 
5. 
 
Graduate 
 
35 
 
27 
 
8 
 
 
Majority of the affected cases are educated upto primary level i.e, low educational status. 
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TABLE – 6 
OCCUPATION WISE DISTRIBUTION OF CASES 
S.NO OCCUPATION TOTAL MALE FEMALE 
1. Farmer 75 73 2 
2. Laborer 71 69 2 
3. Driver 36 36 0 
4. Service 21 15 6 
5. Business 8 6 2 
6. Ex military personnel 1 1 0 
7. House wife 123 0 123 
8. Child 7 4 3 
 
Majority of the affected males are farmers and laborers and majority of the affected females are 
house wives. 
TABLE -7 
MARITAL STATUS WISE DISTRIBUTION OF CASES 
 
S.NO. 
 
MARITAL STATUS 
 
TOTAL 
 
MALE 
 
FEMALE 
1. Married 312 182 130 
2. Unmarried 21 19 2 
3. Divorced 2 0 2 
4. Widow 2 0 2 
5. Widower 1 1 0 
6. Child 8 5 3 
 
Married Cases fall under majority. 
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Female
TABLE -8 
ROUTE OF TRANSMISSION  
ROUTE OF 
TRANSMISSION TOTAL MALE FEMALE 
Heterosexual 336 200 136 
Perinatal 8 5 3 
Blood transfusion 2 2 0 
 
The major mode of transmission is heterosexual. 
TABLE – 9 
CD4 COUNT OF HIV REACTIVE CASES 
 
S.NO. 
 
CD4 COUNT 
CELLS/ML 
 
TOTAL  MALE 
 
FEMALE 
1. < 50 15 9 6 
2. 51-100 23 16 7 
3. 101-200 58 37 21 
4. 201-350 80 52 28 
5. 351-500 80 46 34 
6. > 500 90 47 43 
 
Most of the affected males and females have CD4 count >500. 
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TABLE – 10 
AGE WISE DISTRIBUTION OF ORAL CANDIDIASIS CASES IN HIV 
S.NO. AGE GROUP IN YEARS TOTAL MALE FEMALE 
1. 0-10 1 1 0 
2. 11-20 1 0 1 
3. 21-30 17 9 8 
4. 31-40 55 26 29 
5. 41-50 34 26 8 
6. 51-60 21 15 6 
7. > 60 6 4 2 
 
Majority of the affected males and females are in the age group of 31-40 years. 
TABLE – 11 
CD4 COUNT OF ORAL CANDIDIASIS CASES AMONG HIV  CASES 
 
S.NO. 
 
CD4 COUNT CELLS/ML 
 
TOTAL N=135 
 
MALE 
 
FEMALE 
1. < 50 14 10 4 
2. 51-100 17 12 5 
3. 101-200 52 33 19 
4. 201-300 26 12 14 
5. 301-500 24 13 11 
6. > 500 2 1 1 
 
Majority of the cases with oral thrush have CD4 count between 101 -200. 
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TABLE – 12 
AGE WISE DISTRIBUTION OF PULMONARY TUBERCULOSIS CASES IN HIV. 
S.NO AGE GROUP IN YEARS TOTAL N=97 MALE FEMALE 
1. 0-10 1 1 0 
2. 11-20 2 1 1 
3. 21-30 9 6 3 
4. 31-40 47 29 18 
5. 41-50 19 16 3 
6. 51-60 18 13 5 
7. > 60 1 0 1 
 
Majority of the affected males and females are in the age group of 31 to 40 years. 
TABLE -13 
CD4 COUNT OF PULMONARY TB CASES IN HIV. 
S.NO. CD4 COUNT CELLS/ML TOTAL MALE FEMALE 
1. < 50 15 10 5 
2. 51-100 20 15 5 
3. 101-200 36 25 11 
4. 201-300 12 4 8 
5. 301-500 9 7 2 
6. > 500 5 5 2 
 
Majority of the affected cases have CD4 count between 101-200. 
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TB + HIV Cases
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Male
Female
TABLE -14 
AGE WISE DISTRIBUTION OF HSV-2 CASES IN HIV. 
S.NO. AGE GROUP IN YEARS TOTAL MALE FEMALE 
1. 0-10 - - - 
2. 11-20 1 1 0 
3. 21-30 1 1 0 
4. 31-40 30 16 14 
5. 41-50 10 9 1 
6. 51-60 7 5 2 
7. > 60 1 1 2 
 
The prevalence of HSV-2 in HIV increases with increasing age with majority falling in 
the age group 31 to 40 years. 
TABLE – 15 
CD4 COUNT OF HERPES SIMPLEX-2 CASES IN HIV. 
 
S.NO. CD4 COUNT 
CELLS/ML 
 
TOTAL N=50 
 
MALE 
 
FEMALE 
1. < 50 2 2 0 
2. 51-100 4 2 2 
3. 101-200 24 15 9 
4. 201-300 15 9 6 
5.  >300 5 5 0 
 
Majority of the HSV-2 + HIV infected have CD4 counts between 101 – 200. 
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TABLE – 16 
AGE WISE DISTRIBUTION OF TOXOPLASMOSIS CASES IN HIV. 
S.NO. AGE GROUP IN YEARS TOTALN=20 MALE FEMALE 
1. 0-10 - - - 
2. 11-20 - - - 
3. 21-30 2 2 0 
4. 31-40 8 4 4 
5. 41-50 4 3 1 
6. 51-60 5 5 0 
7. > 60 1 1 0 
 
Majority of the cases are in the group of 31 to 40 years. 
TABLE – 17 
CD4 COUNT OF TOXOPLASMOSIS CASES IN HIV. 
S.NO. CD4 COUNT CELLS/ML TOTAL N=20 MALE FEMALE 
1. < 50 2 1 1 
2. 51-100 3 3 0 
3. 101-200 6 5 1 
4. 201-300 9 6 3 
 
 Majority of the affected cases have CD4 count between 201-300. 
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TABLE – 18 
AGE WISE DISTRIBUTION OF CRYPTOCOCCOSIS CASES IN HIV. 
S.NO AGE GROUP IN YEARS TOTAL MALE FEMALE 
1. 0-10 - - - 
2. 11-20 - - - 
3. 21-30 1 0 1 
4. 31-40 4 2 2 
5. 41-50 2 2 0 
6. 51-60 5 3 2 
 
Majority of the affected cases are in the age group of 51-60 years. 
TABLE – 19 
CD4 COUNT OF CRYPTOCOCCOSIS CASES IN HIV. 
S.NO. CD4 COUNT CELLS/ML TOTAL MALE FEMALE 
1. < 50 3 1 2 
2. 51-100 4 2 2 
3. 101-200 5 4 1 
 
Majority of the affected cases have CD4 count between 101 to 200. 
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DISCUSSION  
Infection with HIV imposes heavy suffering on the affected individuals and in developing 
countries like India it imposes a great burden on the economy. All the health problems in HIV 
are due to waning immunity and the opportunistic infections in HIV are significant causes of 
mortality and morbidity and they pose a great challenge to the era of modern medicine having a 
great impact on the quality of life in HIV affected individuals. 
Due to its non curable status, AIDS continues to be a major health problem. The primary 
medical care in India for HIV mainly consists of supportive treatment for symptoms, prophylaxis 
& treatment of Opportunistic infections. So early diagnosis of HIV and its opportunistic 
infections is vital.  This study was done with 346 reactive cases in Thanjavur and the prevalence 
is about 2.8% which is high when compared to the overall prevalence of HIV in Tamil Nadu 
which is about 0.47%. The high prevalence of HIV in Thanjavur  makes it necessary  to evaluate 
the seropositivity, the immune status and the spectrum of Opportunistic Infections (56). 
AGE WISE PREVALENCE : 
In my study majority of the patients were in the age group of 31 to 40 years followed by 
41 to 50 years. This observation matches with that of other workers and that of  NACO. Nilanjan 
Chakrabothy et al, ICMR unit, Kolkata has shown that majority of them were in the age group of 
31 to 40 years followed by 21-30 years. Aruna Agarwal et al has shown that most of the cases 
were in the reproductive age group. Similar observation is shown by Jagdish et al. Kesav Singh 
et al has shown that majority of them are in reproductive age group of 15 to 45 years (9, 35, 43, 
62). 
 
SEX WISE PREVALENCE : 
In my study, majority( 60%) are males. A study by NACO has shown males predominate 
with 61%. This observation matches with studies of  Aruna Agarwal et al and Kesav Singh et al 
and Sarna A et al (9, 43). Nilanjan Chakrabothy et al has shown in his study that 84% were 
males and 16% were females. But in a study by Akinsegun Akinbomi et al(3) done in Nigeria 
has shown that 56% were females and 44% were females with a male female ratio 1: 1.8 with a 
female preponderance. 
A majority of the subjects were from rural areas about 77.17% and 22.83% were from 
urban areas. Similar results are observed by NACO, Aruna Agarwal et al and Kesav Singh et al 
and Sarna A et al. Nilanjan Chakrabothy et al. This shows that awareness about AIDS is very 
much low in rural areas. Vyas N et al in his study done in North west India has also shown 
similar observations. 
 
EDUCATION WISE PREVALENCE : 
Most of the subjects were educated upto primary level (35.55%) followed by illiterates 
(32.66%). This indicates that most of the subjects have a low educational status. This is similar 
to the study conducted by Jayaram et al. But in a study by Kesav Singh et al done at Rewa 
district of Madhya Pradesh most of them were educated upto secondary level. In my study 56% 
of females were illiterate which is in contrast to a study by Gupta et al where 28% of the females 
were illiterate(29, 38, 43). 
 
OCCUPATION   WISE PREVALENCE : 
Occupation wise majority were farmers(21.68%) and laborers (20.52%) who may 
indulged in risky activities because of illiteracy and lack of awareness. Similar observations are 
shown by most other workers. Among the males, 10.4% were drivers whereas in a study by 
Kesav Singh et al 21.68% were drivers and Vyas N et al has shown that 9.7% were drivers.  
Among the females, 88.49% were house wives. Kesav Singh et al has shown that 77.27% were 
house wives but a study done in Udippi has shown that only 44.5% were house wives (43,84). 
MARITAL STATUS : 
The distribution according to the marital status has shown that 90.17% were married and 
6.07% were unmarried, 0.58% were widows and 0.29% were widowers. Among the males 
87.92% were married and 9.18% were unmarried. Among the females 93.53% were married and 
1.44% were unmarried. This is similar to the study done by Lal et al in North west India but 
Kesav Singh et al in his study has shown that 76.92% of males and 73.92% of females were 
married(43, 47).   
ROUTE OF TRANSMISSION : 
In my study the major route of transmission is heterosexual 97.11%, followed by 
perinatal transmission (2.31%) and blood transfusion (0.58%). Kesav Singh et al has shown 
heterosexual mode of transmission in 89.33%, perinatal transmission in 21%.  Jagdish et al has 
shown heterosexual mode of transmission in 95.73%, perinatal transmission in3.4%. Nilanjan 
Chakrabothy et al has shown heterosexual mode of transmission in 80.33%, homosexual 
transmission in 6%, Injectable Drug Use in 16% and blood transfusion in 2.9% (35, 61). 
CLINICAL PROFILE : 
Fever(53%), weight loss(50%) followed by oral thrush (39%) and cough(30%) were the 
most common presenting features in my study which is supported by Aruna Agarwal et al who 
showed Fever(56%), weight loss(31%) followed by oral thrush (30%) and cough(50%) and 
Jagdish et al showed Fever(57%), weight loss(45%) followed by cough(18%). Anant A Takalkar 
et al showed Fever(85%), weight loss(65%) , cough(47%) and diarrhea in (41.77%) (4, 9,35). 
CD4 STATUS : 
Majority of the patients had CD4 counts > 500, followed by  200 to 500.  Only about 
30% of the patients had CD4 below 200. In my study CD4 status of the patients reveal that HIV 
is diagnosed at an earlier stage when the immune system is not much damaged. One more 
important finding is that the chances of getting opportunistic infection increases when CD4 falls 
below 200. In a study by Anant A Takalkar et al about 46.4% had CD4 < 200. Akinsen et al has 
shown that 42.4% had CD4 < 200. Whereas in a study conducted in New Delhi and in a study 
done by Gerardo et al most of the patients had CD4 < 200 reflecting late presentation of HIV (3, 
4, 27). 
OPPORTUNISTIC INFECTIONS – ORAL CANDIDIASIS : 
In my study, oral candidiasis is the most common opportunistic infection 135 cases out of 
the 346 reactive cases (39.02%) had oral thrush. This finding correlates with the study of 
Shobana et al who has shown 36% of oral candidiasis and the study of Anant A Takalkar et al 
who has shown 39% of oral candidiasis and Aruna et al has shown a prevalence of 24.24% (9). 
In contrast, studies by Pande S et al, Nair S et al, Mulla S A et al has shown a low prevalence of 
oral thrush of 22.7%, 16.5% and 19.4% respectively. Oral Candidiasis emerged as the most 
frequent infection associated with HIV (4, 54, 64, 72). 
PULMONARY TUBERCULOSIS : 
Pulmonary Tuberculosis emerged as the second common Opportunistic Infection 
following Oral thrush. 97 cases out of 346 cases (28.02%) showed Sputum smear positivity. But 
the most common presenting clinical feature in my study was fever (53%) and weight loss(50%) 
which can be attributed to Extrapulmonary Tuberculosis which is more common in HIV than 
Pulmonary TB and this entity was not studied. But in most studies which included EPTB, TB 
remained the first and foremost Opportunistic Infection. For example, studies by authors like 
Anant A Takalkar et al, Pande S et al, Zaheer M S et al, Singh A et al has shown a prevalence of  
52.3%, 54.7%,57% , 56.0% respectively. But Jagdish et al has shown a prevalence of 25% which 
matches with my study. TB is highly endemic in India and multi drug resistance is common in 
HIV (4, 35, 50, 64, 73, 86). 
HERPES SIMPLEX – 2: 
The viral opportunistic infections in HIV/AIDS has become more common causing 
significant health problems in our community. Out of the 346 sera screened for HSV-2 IgG 
antibodies, 50 were seroreactive(14.45%). The low prevalence of  HSV-2 in my study may be 
due to geographic and socio-economic factors. Nilanjan Chakrabothy et al(63) has shown a 
prevalence of 47% in his study.HIV infection is associated with increased risk of Human Herpes 
Viruses and their related disorders.  Genital ulcers are the most common cause of disruption of 
epithelial barrier and infiltration of CD4 locally resulting easy and early acquisition of HIV. K 
Anuradha et al has shown a prevalence of 22%. Flemming et al and Varela et al has shown a 
prevalence of  21% and 25%  of HSV-2 in general population respectively(7). HSV-2 
reactivation enhances the transmission of HIV. Immune deficiency in HIV decreases the 
inflammatory response of the host and therefore the lesions are not evident(28). 
TOXOPLASMOSIS : 
Out of the 346 sera screened for Toxoplasma IgG antibodies, 20 were reactive (5.78%). 
The prevalence of Toxoplasmosis in HIV varies from 3 to 97%. Studies have shown that the 
prevalence of Toxoplasma in USA is 10-40%, in Asia 10-50% and in Europe it varies from 4-
90%. The increased prevalence of Toxoplasmosis may be due to behavioural changes induced by 
the parasite (25). In the pre-ART era, toxoplasmosis presented mostly as encephalitis but now 
disseminated forms involving lungs, eyes and spinal cord are common. This is the most 
important cause of Neurological Immune Reconstitution Inflammatory Syndrome( 15, 25, 53, 
76). 
CRYPTOCOCCOSIS : 
Out of the 346 sera screened for Cryptococcosis by Latex Agglutination Test, 12 were 
reactive (3.41%). It is caused by inhalation of spores of the fungus. The infection remains 
dormant. When immunity falls in case of HIV and CD4 count falls below 100, the infection is 
reactivated and spreads. Usually presents as meningitis and half of them die. The case load is 
high in Subsaharan Africa followed by South east Asia. The incidence of Cryptococcal 
meningitis varies. It is 3.6% in U.K., 4.5% in France, 6% in USA and 3% in India.  It is a 
common Opportunistic infection in HIV but remains undiagnosed due to lack of awareness. 
Mostly it presents as chronic meningitis but can present as acute meningitis also. So 
Cryptococcal meningitis should be ruled out in any HIV patient presenting with nausea and 
vomiting. WHO released “Rapid Advice”  guidelines for diagnosis, prophylaxis and 
management of Cryptococcosis (30,77). 
AMPLICOR HIV-1 DNA PCR : 
10 samples were run and all the samples(100%) answered positive. Satarupa Sengupta et 
al has shown 100% positivity in her study done in Kolkata. JCM accepts study has shown a 
positivity of 93.3%. One sample answered negative due to low viral load. The quantification of 
HIV-1 DNA by nucleic acid based methods like PCR is necessary for evaluating the efficacy of 
ART therapy. It is also of great use in diagnosis of HIV in infants and adults in window 
period(23, 39, 69). 
LIMITATIONS OF STUDY: 
1. Opportunistic Infections other than Oral Candidiasis, Pulmonary Tuberculosis, Herpes 
Simplex-2, Toxoplasmosis and Cryptococcosis like Extrapulmonary Tuberculosis, 
Cryptosporidiasis, Pneumocystis jiroveci Pneumonia, CMV retinitis etc., were not 
studied due to lack of facility. 
2. HIV-1 Subtyping was not done. 
3. The study was limited to one centre. 
 
 
 
 
SUMMARY 
The present study was done at Thanjavur Medical College Hospital from September 2012 
to September 2013 to find the seroprevalence of HIV and the spectrum of Opportunistic 
Infections associated with HIV. 
• The sera of the patients were tested by HIV COMB-AIDS. 
• The reactive sera were further tested by HIV Triline and HIV Trispot and the sera 
reactive by the three rapid tests were further confirmed by HIV Micro ELISA. 
• Seroprevalence of HIV was 2.8% 
• Preponderance of HIV was found more in males when compared to females and the 
common age group of the reactive cases was 31 to 40 years and majority  were from rural 
areas and educated upto primary level. 
• Majority of the males were farmers and most females were housewives. 
• Majority of them were married and heterosexual route remained the predominant mode of 
transmission. 
• One forth of the patients had CD4 count above 500 and one forth had CD4 counts < 200 
cells. So most of them had good immune status at the time of diagnosis. 
• Oral Candidiasis emerged as the most common Opportunistic Infection followed by 
Pulmonary Tuberculosis, Herpes Simplex Virus -2, Toxoplasmosis and Cryptococcosis. 
• Molecular Characterisation was done for 10 samples by RT-PCR and all answered 
positive. 
CONCLUSION 
• This study highlights the epidemiological data and clinical presentation of HIV infection 
in and around Thanjavur. 
• From this study, the role and the complex interrelationship between various social and 
demographic factors can be understood and thereby the transmission of HIV can be 
controlled and interrupted. 
• The common age group of affected patients in this study is 31 to 40 years. This data 
highlights the need of intervention programmes like HIV awareness and safe sex 
education among the young adults. 
• This study shows increasing trend of HIV infection spread among the house wives which 
has a direct impact on perinatal transmission and increased number of Paediatric AIDS. 
This has a powerful influence on the socio – economic and cultural development of a 
country. 
• This study is aimed at providing base line data regarding the common Opportunistic 
Infections prevalent in our part thereby helps the physicians to take prompt therapeutic 
measures. 
• Since most patients are diagnosed of HIV only when they present with Opportunistic 
Infections, a high level of alertness is needed both at the clinical and laboratory level and 
routine surveillance becomes mandatory. 
Though curative treatment for HIV is not available at present, we can minimize the HIV 
infection by early screening and health education. 
 ANNEXURES 
INFORMED CONSENT 
 I have been informed about the study on HIV infection. I am willing to give sample for 
the study, as I realize the importance of the study. I am also aware that I can withdraw from the 
study whenever I like. 
 
Date :        Signature of the patient 
Department : 
CLINICAL PROFORMA 
Name of the patient:     Serial No. : 
     Age :       Lab No. : 
Sex :       OP/IP No. : 
     Address :       Date Of Sample Collection : 
     Occupation :      Income : 
     Chief Complaints : 
1. Fever 
2. Cough 
3. White patches in oral mucosa 
4. Loss of weight 
5. Loss of appetite  
    Past History : 
1. Tuberculosis 2. Bronchial asthma 3. Diabetes 4. Hypertension. 
  Family History : 
  Personal History :  
1. Smoker 2. Alcoholic 3. Extra marital contact 4. Injectable Drug Use. 
 
CLINICAL DIAGNOSIS : 
LABORATORY FINDINGS 
1. HB% 
2. WBC 
3. PLATELET COUNT 
4. HAEMATOCRIT % 
5. LIVER ENZYMES 
6. OTHER INVESTIGATIONS 
7. HIV RAPID TEST : 
8. HIV MICROLISA 
9. MOLECULAR DIAGNOSIS 
10.  GRAM STAINING & CULTURE FROM ORAL THRUSH 
11. SPUTUM AFB 
12. HSV-2 IgG ELISA 
13. TOXOPLASMOSIS IgG ELISA 
14. CRYPTOCOCCAL LATEX AGGLUTINATION TEST : 
 
Name 
AGE/ 
Sex HABITAT EDUCATION OCCUPATION 
MARITAL 
STATUS ROUTE 
CD 
4COUNT TB, OC HSV-2    CRY 
 
TOXO 
Aravindhan 18/M rural sec student nm heterosexual 330 nil       
Madhumitha 7/F rural       perinatal 432 nil       
Navab 43/M rural sec labourer m heterosexual 87 TB, OC       
Vahidha 35/F rural Primary HW m heterosexual 1032 nil       
Yelambal 55/F rural Illiterate HW divorced heterosexual 40 TB, OC       
Ayyadurai 43/M rural Primary labourer m heterosexual 370 OC       
Manimaran 24/M urban sec driver um heterosexual 653 nil       
Uma 32/F urban sec hw m heterosexual 471 nil       
Senthilkumar 34/M rural Primary labourer m heterosexual 830 nil       
Rajamani 39/F rural Primary farmer divorced heterosexual 95 TB, OC       
Indhira 40/F rural Illiterate farmer widow heterosexual 175 TB, OC,  hsv     
Mahalakshmi 33/F urban graduate hw m heterosexual 665 nil       
Saravanan 31/M urban sec labourer m heterosexual 142 TB, OC hsv     
Karthi 23/F rural sec hw m heterosexual 389 OC       
P.Rani 45/F rural sec hw m heterosexual 760 nil       
Rani 50/F rural sec hw m heterosexual 131 OC hsv     
Pitchaipillai 39/M rural Primary farmer m heterosexual 100 Tb hsv   toxo 
Thangaraj 43/M urban graduate service m heterosexual 108 oc, hsv hsv     
Vimala 28/F rural sec hw m heterosexual 720 nil       
Raman 28/M rural Primary farmer m heterosexual 501 nil       
Ravi 28/M rural Illiterate labourer m heterosexual 694 nil       
Indhirani 35/F urban Illiterate hw m heterosexual 751 nil       
Mahalakshmi 35/F rural sec hw m heterosexual 184 oc hsv     
Rengan 30/M rural Illiterate farmer m heterosexual 223 oc     toxo 
Udayasankar 46/M rural sec driver m heterosexual 313 nil       
Subbaiyan 57/M rural sec farmer m heterosexual 564 nil       
Shyamala 24/F urban Primary hw widow heterosexual 639 nil       
Sureshbabu 30/M rural sec labourer m heterosexual 854 nil       
Mari 47/m rural Primary farmer widower heterosexual 813 nil       
Sujatha 37/F rural sec hw m heterosexual 231 oc hsv     
Selvaraj 44/M rural Primary driver m heterosexual 453 nil       
 
 
1. COMB AIDS, Triline, Trispot kits 
 
 
 
 
 
 
 
 
 
 
 
2. Immuno chromatography – Non reactive for HIV 
 
 
 
 
 
 
 
 
 3.  Immuno chromatography –  Reactive for HIV-1 
 
 
 
4. Immuno chromatography – Reactive for HIV-1 & 2 
 
 
 
 
 
5. ELISA Reader
 
 
6. HIV Microlisa kit 
 
 
 
 
 
 
 
7. HIV Microlisa 
8. BD FACS Count System
– Test Results 
 
 
 
 
 
9. Sputum AFB Positive 
 
10. Candida growth in SDA. 
 
 
11. HSV-2 IgG ELISA – Test Results 
 
12. Toxoplasmosis IgG ELISA kit 
 
 
 13. Cryptococcosis Latex Agglutination Kit 
 
 
 
 
 
 
 
 
 
 
 
14. Cryptococcosis Latex Agglutination – Test Results 
 
 
 
 
 
 
15. Thermal Cycler 
 
 
 
 
 
 
 
 
16. AMPLICOR HIV-1 DNA PCR kit 
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